Asymmetric Independence Model for Detecting Interactions between
  Variables by Yu, Guoqiang et al.
Asymmetric Independence Model for
Detecting Interactions between Variables
Guoqiang Yu∗
Dept. of Electrical and Computer Engineering, The Virginia Polytechnic Institute and State University,
Arlington, VA, USA.
David J. Miller
Dept. of Electrical Engineering, The Pennsylvania State University, State College, PA, USA.
Carl D. Langefeld
Dept. of Biostatistical Sciences, Wake Forest University, Winston-Salem, NC, USA.
David M. Herrington
Dept. of Internal Medicine, Wake Forest University, Winston-Salem, NC, USA.
Yue Wang
Dept. of Electrical and Computer Engineering, The Virginia Polytechnic Institute and State University,
Arlington, VA, USA.
Summary. Detecting complex interactions among risk factors in case-control studies is a funda-
mental task in clinical and population research. However, while hypothesis testing using logistic
regression (LR) is a convenient solution, the LR framework is poorly powered and ill-suited under
several commonly occurring circumstances, including missing or unmeasured risk factors, imper-
fectly correlated “surrogates”, and multiple disease sub-types. The weakness of LR in these settings
stems from the way the null hypothesis is defined. Here we propose the Asymmetric Independence
Model (AIM) as a biologically-inspired alternative to LR, based on the key observation that the
mechanisms associated with acquiring a “disease” versus maintaining “health” are asymmetric.
We prove mathematically that, unlike LR, AIM is a robust model under the abovementioned con-
founding scenarios. Further, we provide a mathematical definition of a “synergistic” interaction,
and prove theoretically that AIM has better power than LR for such interactions. We then exper-
imentally show the superior performance of AIM compared to LR on both simulations and four
real datasets. While the principal application here involves genetic or environmental variables in
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the life sciences, our methodology is readily applied to other types of measurements and inferences,
e.g. in the social sciences.
Keywords: complex interaction; logistic regression; asymmetric independence model
1 Introduction
The problem of detecting statistical interactions between multiple factors that influence disease
risk, treatment efficacy, or other complex human traits is pervasive in genetics, epidemiology,
pharmacology, and social sciences, e.g. (Martinelli(1999)), (Castellsague(1999)), (Mallal(2008)),
(Rosing(1999)), (Orkunoglu-Suer(2008)). In genetic studies, including candidate gene studies
and genome-wide association studies (GWAS), once main effects are detected, finding gene-gene
and gene-environment interactions may give crucial clues to the underlying biological mecha-
nisms/pathways in play ( Matsuo(2001)), (Braun(2011)). Detection of interactions may also help
to identify subpopulations that would benefit from, or be harmed by a particular drug treat-
ment/intervention option, e.g. the effect of the anti-HIV drug abacavir in individuals with the
HLA-B*5701 allele (Mallal(2008)). More generally, in the life, social, and physical sciences, detec-
tion of interaction effects can help generate new hypotheses or illuminate novel etiologic mecha-
nisms. In all of these settings a statistical interaction is in general present when, as measured over
a finite population, the joint effect of multiple risk factors or predictors differs, in a statistically
significant fashion, from the expected baseline joint effect that would occur if these factors act inde-
pendently. Inference on the presence of such interactions amongst a set of target factors should not
be confused with the related, albeit quite distinct task of detecting novel risk factors by incorpo-
rating both interaction effects and (possibly weak) main effects (Marchini(2005)),(Cordell(2009)).
While detecting interactions is ubiquitous, the technical challenge associated with this inference
task is very different from that associated with other statistical inference tasks. To elaborate,
correctness of hypothesis testing rests heavily on the null hypothesis, while efficiency or power
is often determined by the alternative hypothesis. For many inference tasks, the proper choice
of the null model is plainly obvious and methodological development therefore focuses on tuning
the alternative model to make it as sensitive as possible to enhance detection power. However,
when testing for an interaction, careful specification of the alternative hypothesis is much less
important than the null for the following reason. Although there are potentially different forms of
the alternative hypothesis, they are all essentially the same in that they all involve fully saturated
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models. For instance, to detect an interaction effect that involves two binary variables, at least four
parameters are necessary for the alternative hypothesis (modeling a main effect with two variables
requires three parameters, one for each variable plus one baseline parameter, with the interaction
effect requiring at least one more parameter). Recalling that two binary variables can specify
at most four combinations, a model with four parameters is saturated (Hosmer(2013)), with all
saturated models producing the same likelihood on given data. In contrast, in the setting of a
possible interaction, different null models are not fully saturated and will not in general produce
the same data likelihood. Thus, we argue that, for detecting interactions between factors, the null
model must be carefully designed.
The null is usually called an independence model, describing how multiple factors jointly de-
termine an outcome when there is no interaction between them. In this work, the focus will be on
biological domains, where the outcome is usually a phenotype such as disease or healthy status.
There are multiple non-equivalent ways to define this so-called baseline (null) joint effect. For
example, in epidemiology, if we consider each disease factor to act independently, one model for
baseline disease risk given the presence of multiple factors is the sum of the individual risks coming
from each factor, i.e., an additive model. Alternatively, one can posit that the risk from multiple
independent factors should be the product of their individual relative risks, i.e., a multiplicative
baseline model (Gonzalez(2005)). Several other baseline models that have been previously proposed
are reviewed in the Discussion section; however, they are all variants of these two principal models.
Since these models are all mathematically valid, with each describing one class of possible baseline
effects, it may appear that there is no objective basis for preferring one baseline effects model over
another. However, we argue such basis can be found in the relationship both to existing knowledge
and to practical considerations: 1) consistency of the model with existing theories/knowledge of
the domain (where, here, the focus will be on biological domains involving a “disease status” phe-
notype); 2) any useful theoretical properties that accrue to the model and bear on its suitability
in practice. As will be explained shortly, it turns out that the existing models have severe limita-
tions undermining these two principles. These limitations are not only conceptual and theoretical.
Significant implications such as inflated type I error and reduced power are observed and will be
illustrated in the sequel. All of this inspired us to develop an alternative baseline effects model.
To help motivate this new model, it is instructive to first consider for comparison the typical LR
framework that is both familiar and widely applied.
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Logistic Regression for Interaction Detection
Suppose there are N binary factors, i.e. X = (X1, X2, . . . , XN ), Xi ∈ {0, 1}, a binary health
status variable C ∈ {0, 1} (‘case’ = 1, ‘control’ = 0) and let P (C = c|X), c = 0, 1, denote the
posterior probability on health status. Baseline logistic regression (LR) posits a log-linear odds
ratio, i.e.
log
P (C = 1|X)
P (C = 0|X) =
N∑
i=1
βiXi + β0, (1)
or, equivalently, that
P (C = 1|X) = e
N∑
i=1
βiXi+β0
1 + e
N∑
i=1
βiXi+β0
, (2)
where β = (β0, β1, . . . , βN ) are the model parameters, estimated based on the given case-control
population. An interaction between factors Xi and Xj (and, thus, formation of the alternative
hypothesis) is introduced by adding a multiplicative term γijXiXj to the exponents in (2). The
candidate interaction’s significance is measured by choosing as the test statistic twice the difference
between the population’s data log-likelihood based on the model that includes the interaction term
and the log-likelihood for the baseline model. According to Wilks’ theorem (Wilks(1938)), this
statistic asymptotically follows a chi-squared distribution.
There are several points supporting use of the logistic regression framework to specify the
baseline (null) model. First, the range of the log-transformed odds ratio matches that of a linear
combination of predictor factors, as both span the whole real line. Second, the maximum likelihood
optimization problem for estimating the LR model parameters β is convex and thus amenable to
standard optimization techniques that yield globally optimal parameter estimates. Finally, there
is great familiarity with LR and wide availability of LR modeling software in standard statistical
packages. Accordingly, LR (Agresti(2002)) and its case-only study form (Cordell(2009)), (Van-
derweele(2011)) have become de facto standards for detecting interactions in case-control studies
in genetics, medicine, and in the social sciences. However, there are several limitations of this
approach, outlined below.
Theoretical Limitations of the LR Null
In general, the “correct” null form is both unknown and domain-dependent. Thus, in choosing a
model one must be guided by several desiderata: 1) theoretical plausibility – is the model derivable
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starting from plausible assumptions and domain knowledge ?; 2) model parsimony; 3) model robust-
ness in the face of commonly occurring confounding effects; 4) experimental support/validation. In
the case of LR, several considerations are not well met, as outlined below.
LR framework is (in some instances) biologically implausible
LR is not particularly inspired by nor derivable from an underlying conceptual model of disease
risk. Indeed, it was originally proposed to model population growth (Verhulst(1838)). One feature
of LR that is explicitly inconsistent with many models of disease is its symmetry or exchangeability
with respect to the class label status. Specifically, when modeling the relationship between two
or more risk factors and a binary disease outcome, a common conceptual model is that one may
get the disease if any of the risk factors are penetrant or active, whereas being healthy requires
all of the factors to be inactive. This conceptual model is inherently asymmetric with respect
to the two statuses, disease and health. However, in LR, the two statuses are exchangeable and
the model is thus symmetric, i.e. log(PLR(C = 1|X)/PLR(C = 0|X) =
N∑
i=1
βiXi + β0 , and if
we swap disease and health labels, that is, C = 1 ⇔ C ′ = 0 and C = 0 ⇔ C ′ = 1, we have
log(PLR(C
′ = 1|X)/PLR(C ′ = 0|X) =
N∑
i=1
(−βi)Xi + (−β0). That is, the LR form is invariant
to label swapping; moreover, the data likelihood, with estimated parameters plugged in, is also
invariant to label swapping. That is, for LR it does not matter whether the case group is defined
to consist of disease or healthy subjects. Equivalently, under LR, one does not require all the risk
factors to be inactive in order to be healthy. Even without more detailed consideration, LR, as a
symmetric health status model, thus appears to be in conflict with a common conceptual model of
disease risk.
Invalidity of LR in the setting of missing or surrogate causal factors
Another important consideration, in choosing a model, concerns its “robustness” in the face
of confounding effects that are common in practice. The prevailing scenario in inquiry involving
complex diseases is that one has incomplete knowledge of the true risk factors. Such “incomplete-
ness” may take several forms, e.g. 1) missing, i.e. unmeasured factors and 2) measured factors that
are surrogates which are not perfectly correlated with the true factors. There are several reasons
why some true factors may not be measured. First, for many diseases, it is quite likely there are
causal agents that have not yet been discovered or even postulated as part of prevailing theories
and models. Given that many environmental factors may only contribute to disease through gene-
environment joint effects, which are only recently being extensively investigated, one can expect
that many environmental agents may have been overlooked to date. Second, even if known, some
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variables are difficult and/or costly to measure, and their measurement may also be unacceptably
invasive. Thus, one would expect that it is the rule, rather than the exception, that some causal
factors are missing from a given case-control study design. Much of the same reasoning leads to
the conclusion that, rather than the true causal agents, most studies will also involve some sur-
rogate factors, at best (relatively) strongly correlated with the true agents. Again, this may be
attributable to an imperfect working theory, and also to considerations of cost, convenience, and
privacy in data measurement and collection.
We would expect that our chosen model should behave robustly in the presence of these effects
in particular, that they can be accurately compensated for through suitable choice of the models
parameter values. However, the LR parametric form is not invariant to these two effects and there
is no way to “correct” the LR model for these potentially confounding effects in practice. As an
example, suppose there are three binary causal factors (N = 3) and that the LR baseline joint
effects model, when all three binary causal factors are observed, has parameter values: β0 = −4,
β1 = 2, β2 = 2, and β3 = 2. Table 1 shows the disease probability under each of the eight
combinations. Suppose now that the third risk factor X3 is not observed. Further, suppose that
P [X3 = 0] = P [X3 = 1] = 0.5. Then the distribution of the disease probability for this case
(with X3 unobserved) is obtained by averaging the left and right sub-tables of Table 1. The new
distribution is shown in Table 2. Assuming that the LR model form is preserved when X3 is not
observed, let us denote by β′0, β′1, and β′2 the parameter values for the new LR model. As there are
three parameters, any three combinations from the four combinations in Table 2 suffice to calculate
the parameters. We choose to compute these by excluding (X1 = 1, X2 = 1), as follows:
β′0 = log
(
P (C = 1|X1 = 0, X2 = 0)
1− P (C = 1|X1 = 0, X2 = 0)
)
= log
(
0.0686
1− 0.0686
)
= −2.6084
β′1 = log
(
P (C = 1|X1 = 0, X2 = 1)
1− P (C = 1|X1 = 0, X2 = 1)
)
− β′0 = log
(
0.3096
1− 0.3096
)
+ 0.0711 = 1.8064
β′2 = log
(
P (C = 1|X1 = 1, X2 = 0)
1− P (C = 1|X1 = 1, X2 = 0)
)
− β′0 = log
(
0.0686
1− 0.0686
)
+ 0.0711 = 1.8064
The odds for the combination (X1 = 1, X2 = 1) based on the LR model is:
P (C = 1|X1 = 1, X2 = 1)
1− P (C = 1|X1 = 1, X2 = 1) = e
β′0+2β
′
1 = 2.7385. (3)
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However, from Table 2, the odds for (X1 = 1, X2 = 1) is
0.6904
1−0.6904 = 2.2300. Thus, the as-
sumption that the LR form is preserved when there are missing factors (i.e., that estimating new
LR parameter values only for the observed factors is equivalent to marginalizing over the missing
factors) is contradicted in this example and, thus, as a general rule.
X3 = 0 X3 = 1
P X2 = 0 X2 = 1 p X2 = 0 X2 = 1
X1 = 0 0.0180 0.1192 X1 = 0 0.1192 0.5000
X1 = 1 0.1192 0. 5000 X1 = 1 0.5000 0. 8808
Table 1. Posterior probability of disease, with all risk factors observed, under the logistic
regression model.
p X2 = 0 X2 = 1
X1 = 0 0.0686 0.3096
X1 = 1 0.3096 0.6904
Table 2. Posterior probability of disease, with risk factor X3 missing, under the logistic
regression model.
In a similar fashion, also by counterexample, one can show that the LR form is also not invariant
to observation of surrogate factors, imperfectly correlated with the true factors, rather than the
true ones. That is, properly accounting for the correlation structure between measured surrogates
and their “upstream” causal factors does not preserve the LR model parametric form. This is
demonstrated in Appendix A. “Correcting” the LR model to account for these effects would require:
1) initially, estimating the “true” LR model (based on observation of all causal factors) and then
2) transforming this model to account for the missing (or surrogate) causal factors. In the missing
7
factor case, step 2 would involve marginalizing out the missing factors while in the surrogate factor
case, it would involve accounting for the correlation structure between surrogate and causal factors
(see Appendix A). However, since in practice it is unknown which (and how many) causal factors
may be missing (or replaced by surrogates) and since, anyway, under these two scenarios, there
are no data observations for these causal factors, there is no way to implement either of these two
correction steps. Thus, both missing causal and surrogate factors are confounding effects for LR,
with no way in practice to correct the LR model to account for them. In the presence of these
effects, the LR model will be biased which, as will be shown experimentally below, results in inflated
type 1 error. Since the case-only LR approach (Cordell(2009)),(Vanderweele(2011)) is based on the
same principle as LR, it suffers from the same deficiencies. Moreover, case-only is claimed to gain
power over LR through the strong assumption that predictors are independent, which may not be
satisfied in practice.
In the next section, we develop a new model, AIM, which: i) unlike LR, is inspired by an intuitive
underlying disease model; ii) possesses similar model parsimony as LR (i.e., a log-additive form); iii)
is however asymmetric with respect to diseased and healthy statuses; and iv) does possess theoretical
invariance properties that make the model robust to missing and surrogate factors. Moreover, the
model possesses other attractive properties (consistency under multiple disease sub-types). Finally,
we give a precise, operational definition of a type of interaction commonly encountered in practice
– “synergistic” – for which we mathematically prove that AIM has greater detection power than
LR. In a variety of experiments involving “synergistic” interactions, using both real and simulated
data sets, we demonstrate substantial gains in power of AIM over LR. Moreover, in controlled
simulation experiments to investigate the effects of missing, surrogate factor, and complex disease
(with subtypes) scenarios, we demonstrate that LR has inflated type 1 error, while AIMs type 1
error is resilient, in the presence of these confounding effects.
2 Asymmetric Independence Model (AIM)
To help develop the AIM model, we first (without any loss of generality) impart a particular
interpretation to the values {0, 1}, taken on by the factor variable Xi – we will construe Xi = 1
as meaning that the i-th disease factor is active, with Xi = 0 indicating the factor is inactive. We
then make the following two assumptions, which together determine the form of the AIM model.
Assumption 1: Factors independently exert effects on health status (‘diseased’ or ‘healthy’). This
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assumption translates mathematically as follows. We define a latent “local” binary disease status
random variable Ci ∈ {0, 1} coupled to each factor Xi, i.e. with the Ci assumed statistically
independent of each other given the status of Xi. Supposing we have N factors, this assumption
is mathematically equivalent to P [C1, . . . , CN |X1, . . . , XN ] =
N∏
i=1
P [Ci|Xi]. Ci is defined such that
P [Ci = 1|Xi = 0] = 0, i.e. the factor being active is required for the local status to be ‘diseased’.
However, the factor’s active status does not deterministically cause the local status to be ‘diseased’
– it gives propensity for the local status to be diseased, based on the conditional probability
φi ≡ P [Ci = 1|Xi = 1]. How the individual local disease statuses jointly contribute to/determine
the global disease status C is specified next.
Assumption 2: an individual is healthy only if every factor that is active does not cause its local
status to be ‘diseased’, i.e. C = 0 ⇔ (C0 = 0) ∩ (C1 = 0) ∩ (C2 = 0) · · · (CN = 0). Here, C0 is a
“background” factor accounting for sporadic disease occurrence, with probability φ0 ≡ P [C0 = 1].
Stochastic Data Generation
The above two assumptions fully specify a stochastic data generation mechanism for the disease
status C given an observed factor vector X = x, as follows: 1)Independently randomly generate
Ci given xi, i = 1, . . . , N , according to the probability model defined under Assumption 1, and
randomly generate C0 according to the pmf {1 − φ0, φ0}. 2)Assign C = 0 if (C0 = 0) ∩ (C1 =
0) ∩ (C2 = 0) · · · (CN = 0). Otherwise, assign C = 1.
Posterior Probability Model
The posterior probability of ‘healthy’ status, given a factor vector x, consistent with the above
stochastic data generation, is:
P (C = 0|x) = (1− φ0)
N∏
i=1
(1− φi)xi . (4)
Taking the logarithm, we obtain
logPAIM(C = 0|x) = log(1− φ0) +
N∑
i=1
xi log(1− φi) = β0 +
N∑
i=1
βixi, (5)
where β0 ≡ log(1 − φ0) and βi ≡ log(1 − φi). That is, whereas in logistic regression the log-odds
are linear in the factors, in AIM, the log-probability of health is linear. Exponentiating, we obtain
the AIM posterior probability of healthy status as:
PAIM(C = 0|x) = e
β0+
N∑
i=1
βixi
(6)
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and, thus, with the posterior probability of disease:
PAIM(C = 1|x) = 1− P (C = 0|x) = 1− e
β0+
N∑
i=1
βixi
. (7)
Note that in general we must have 0 ≤ PAIM(C = 0|x) ≤ 1∀x. To ensure this, we would
require β0 +
N∑
i=1
βixi ≤ 0,∀x ∈ {0, 1}N , with number of constraints exponential in N . However,
since the model is being estimated from a finite population X = {x(1), . . . , x(T )} and used solely
for hypothesis testing on this population, the model need only meet these constraints on the given
population, i.e. we really only require β0 +
N∑
i=1
βix
(n)
i ≤ 0,∀x(n) ∈ X .
Note also that while it is possible to do so, we do not constrain the βi to be negative (consistent
with βi being the log of a probability). In this way, the estimated model may contain factors which
attenuate disease risk (eβi , βi > 0) as well as those which amplify this risk (e
βj , βj < 0).
AIM Model Learning and Hypothesis Testing
In Appendix B, we show that AIM’s maximum likelihood (ML) objective function is concave in
the parameters β, with the constrained ML learning problem (concave objective, linear constraints)
thus a convex optimization problem (Boyd(2003)), amenable to finding the global maximum. We
propose a hybrid Newton-Barrier function algorithm for its solution (Appendix C). Statistical
interaction detection for AIM, like LR, is based on a log-likelihood ratio statistic which, under the
null, according to Wilk’s Theorem (Wilks(1938)), is asymptotically chi-squared.
Asymmetry of AIM
As discussed earlier, since mechanisms of being healthy and diseased are different, a model for
disease risk should not bear the same parametric form under both statuses. Recall that LR is a
symmetric model, violating this basic biological constraint. However, AIM is asymmetric, as seen
by noting that while its log-probability of being healthy is a linear function of the factors, the
log-probability of being diseased is clearly nonlinear. Although AIM and LR are thus very different
models, there is an extreme setting under which the two models will coincide. In particular, if
P (C = 1|x) → 1 and, thus, logP (C = 1|x) → 0, we have log(P (C = 1|x)/(1 − P (C = 1|x))) ∼
− log(1 − P (C = 1|x)). In this case, the two models converge to a common model. However, in
practice, the fraction of cases will typically be smaller than the fraction of controls (as cases are
often harder to obtain than controls). In this context, as well as for the other common scenario of
a balanced case-control population, the LR and AIM models are quite different.
Link to Well-Established Biological Theories of Disease
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In addition to its asymmetry, AIM is supported by several well-accepted biological models,
including the heterogeneity theory (McClellan(2010)) and the two-hits theory of cancer (Knud-
son(2001)). The former states that any one of many different mutations in any one of many
different genes leads to related phenotypes. Take hearing loss (McClellan(2010)) as an example.
Here, the responsible genes encode proteins involved in a wide variety of processes in the inner ear,
including development and maintenance of cytoskeletal structures, myosin motors, gap junction
transport and signaling, ion channels, and transcriptional regulators. Consistent with Assumption
2) in our model, if any of these processes fails, the person will lose hearing. It is also reasonable
to have Assumption 1) that factors independently exert effects, due to separation of the functional
modules. The two-hits theory of cancer makes Assumption 1) even more compelling. When one
individual possesses some disease-risk factors (often germline mutations), this is called the first
hit. Disease will not develop until the second hit – random somatic mutation – occurs. Hence,
each disease-risk factor exerts its effect through random somatic mutation. Moreover, in general,
random somatic mutations for different genes are expected to be independent.
While we have argued that AIM is more biologically plausible than LR, we believe the most
compelling support for AIM comes from the invariance of this model, unlike LR, in the presence
of unmeasured, surrogate factor, and disease heterogeneity (subtype) confounding effects.
Model Consistency in the Presence of both Unmeasured and Surrogate Risk Factors
The pervasiveness of missing and surrogate factors (as previously discussed) raises fundamental
questions for models of joint baseline effects: 1) Is the model consistent (i.e. is the model’s form
preserved) when there are missing and surrogate risk factors? 2) If the model form is not preserved,
what are the performance implications? We will resolve 2) empirically through our experiments.
To resolve 1), we have the following theorems, proved in Appendices D-G.
Theorem 1: Assuming statistically independent factors, AIM is a consistent model
when there are unmeasured (missing) causal factors, while LR is not. Moreover, under
the AIM model, the parameter values themselves ({βi}) for the observed factors do
not change, in the presence of missing factors.
Theorem 2: Assume that some causal factors are not measured, but surrogate factors,
correlated with these true factors are instead measured. Assume the following statis-
tical dependency structure: a causal factor Xi is conditionally independent of all other
factors (either the true factors or their surrogates), given the causal factor’s surrogate,
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X0i . Also assume that the disease status is conditionally independent of a surrogate
factor, given the true factor. Then, the AIM model is consistent under the surrogate
factors scenario, while the LR model is not. Moreover, under the AIM model, the
parameter values themselves ({βi}) for the observed true factors do not change, in the
presence of surrogate factors.
Comments:
1) For LR, the theorems are proved by counterexample (as already shown in the previous section
for the unmeasured factors scenario). 2) In the unmeasured case, the new model form is obtained
by marginalizing (integrating out) unmeasured factors. Marginalization of AIM leads to the same
mathematical model form, while this is not true for LR. To understand why the AIM form is
preserved under unmeasured factors, note that PAIM(C = 0|x) = eβ0
N∏
i=1
eβixi . Thus, when a
factor is not measured, it is essentially omitted from the product – this effects marginalization, and
preserves AIM’s log-additive form on the remaining factors (A formal proof is given in Appendix
D.). The proof for consistency under surrogates is given in Appendix E. The practical implication
of these theorems, demonstrated in the Experimental results section, is that LR has inflated type
1 error under these scenarios, while AIM does not. Moreover, AIM has greater detection power
than LR under these scenarios; 3) The rigorous proofs of Theorems 1 and 2 require the assumption
of independence between factors. This assumption may not hold for some applications. We use
simulations to investigate the implications of the violation of this assumption. As shown in section
3.1.5, we do not observe any inflation in type I error rate when there are missing factors, suggesting
Theorem 1 remains practically valid. On the other hand, we do see that Theorem 2 cannot be
true when the independence assumption is violated. However, the effect is not detectable when the
correlation is moderate, and the effect is still small when the correlation is very strong.
Model Consistency Under Disease Heterogeneity
In addition to its consistency under these two confounding scenarios, AIM is also a consistent
model, and LR an inconsistent one, with respect to yet another confounding source – disease
heterogeneity. Specifically, suppose that there are several disease subtypes Di ∈ {0, 1}, i = 1, . . . ,K,
where Di = 1 means the i-th subtype is present in an individual. Likewise, the heterogeneous
disease is present, i.e. C = 1, if and only if at least one disease subtype is present, i.e. if and
only if (D1 = 1)
⋃
(D2 = 1) · · ·⋃(DK = 1). If the different subtypes are known and if the cases in
the population were ground-truth labeled by subtype, one could estimate a separate case-control
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posterior model quantifying the baseline risk for each disease subtype P (Di|x). However, in practice,
this is unrealistic – a complex disease may decompose as subtypes, but these will typically be latent,
with explicit knowledge only of whether the heterogeneous disease is present, not which subtype.
Regardless of whether subtypes are explicitly known or not, there is a posterior for each disease
subtype P (Di|x), i = 1, . . . ,K. Moreover, a model for the complex disease status is the posterior
P (C = 1|x) = P ((D1 = 1)⋃(D2 = 1) · · ·⋃(DK = 1)|x). If the individual subtype models are AIM
models, and if disease subtypes are conditionally independent given the observed factors, then one
can show that the complex disease model is also an AIM model, i.e. the AIM parametric form is
invariant to disease heterogeneity. On the other hand, this is again not true for LR. Specifically,
we have:
Theorem 3: Suppose that a complex disease contains multiple subtypes, which are
assumed to be conditionally independent given the observed factors. Then, the AIM
model form is invariant to disease heterogeneity, i.e. P ((D1 = 1)
⋃
(D2 = 1) · · ·⋃(DK =
1)|x) = PAIM(C = 1|x), where, in particular, the weight βi on an individual factor Xi in
the heterogeneous AIM model is additive over the weights on this factor for each of the
disease subtype models. On the other hand, the LR form is not invariant to disease
heterogeneity.
The proof of this Theorem is given in Appendix F. An important implication of this theorem
is the following: to do inference on the heterogeneous disease using the AIM model, one need not
have any prior knowledge of how many (and whether in fact) multiple disease subtypes exist for
the given disease domain. The AIM modeling approach is naturally accommodating of however
many disease subtypes that may be present (through the additive weight mechanism).
Theoretical Characterization of Detection Power for AIM and LR
Generally speaking, for a two-sided hypothesis testing problem it is difficult to draw a uniform
conclusion on the power comparison between two competing models. In fact, in general a “no
free lunch theorem” should apply, with no model/method uniformly dominating another. Thus,
it is very useful to identify the conditions or assumptions under which one model is theoretically
guaranteed to outperform another. Such results can inform when it is most suitable in practice
to apply one model, rather than another. We have identified conditions under which AIM is
guaranteed to perform better than LR. Strongly supporting the usefulness of AIM, these conditions
correspond to the most common scenarios encountered in real applications. Consider two types of
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interactions: (1) synergistic and (2) antagonistic. A synergistic interaction means that the true
effect associated with the joint occurrence of two risk factors is greater than a baseline model’s
(without interaction) joint effect (Phillips(2008)). On the other hand, if the true joint effect is
smaller than a baseline model’s (without interaction) joint effect, we call it “antagonistic”. Most
interactions found in practice are synergistic (Phillips(2008)). Theorem 4 below, based on a precise,
meaningful, and operational definition of synergistic interactions, shows that AIM has better power
to detect synergistic interactions than LR. A corollary can also be derived stating that LR is
guaranteed better power than AIM for antagonistic interactions. However, even for antagonistic
interactions we argue against the use of LR because of its degraded performance when there are
missing and surrogate factors and/or disease subtypes.
Theorem 4: Given two binary variables X1 and X2, let p00 ≡ P (C = 1|X1 = 0, X2 = 0)
and similarly define p01, p10, and p11. Assume p01 ≥ p00 and p10 ≥ p00. Denote p′11 the
predicted value from the LR model whose three parameters are determined solely by
the true posterior probabilities p00, p10, and p01 (This model is precisely defined in
Appendix G). We define a synergistic interaction as one satisfying p11 ≥ p′11. Under
the above assumptions, we then have the following result: for synergistic interactions,
AIM gives a greater difference between its interaction model and baseline model log-
likelihoods than that for LR. Hence, AIM generates a strictly smaller p-value than LR
and hence has better power to detect interaction effects than LR. Likewise, if p11 < p
′
11,
i.e. an antagonistic interaction, then LR generates a smaller p-value than AIM.
Proof: See Appendix G.
Applicability for Non-binary Factors
Both in the above derivation of AIM and in developing its theoretical properties, we assumed
that factors are binary. All of the above results can be straightforwardly extended for the case
where factors are non-binary but categorical. In particular, a nonbinary categorical variable X
with cardinality L can be recoded as a vector of L binary factors ∈ {0, 1}, with only one of these
factors “on” to specify a value for X. The AIM model can also be applied when the variables Xi are
quantitative (or ordinal). However, the AIM model form is not logically derivable in the same way
as given above for binary factors. Moreover, while AIM’s invariance properties hold for nonbinary
and quantitative factors (since we do not assume factors are binary in the proofs of theorems 1,2,
and 3 given in Appendices D,E, and F, respectively), the rigorous proof of Theorem 4 on detection
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power relies on the assumption of binary factors.
3 Simulation Study
Our simulation study evaluates the type 1 error and detection power of AIM and logistic regression
in a controlled setting, under varying parameter settings which characterize the population being
studied, and under the three confounding scenarios prominently identified in this paper – missing
factors, surrogate factors, and disease subtypes. The goal is to understand the performance effects
of different parameter settings and of these scenarios on both models. These results are next given.
3.1 Evaluation of Type I Errors
Figure 1 shows the Q-Q plot for AIM with 1000 trials. All trials were simulated by randomly
drawing samples from an AIM model with two independent factors and parameters β0 = −0.337,
β1 = β2 = −0.336. The parameters were chosen so that the case-control ratio is around 1 and
the marginal effect size for each factor is an odds ratio of 2. We further assumed all 4 factor
combinations are equally likely. In each experiment, 4000 samples were generated. We can see that
the Q-Q plot closely aligns with the diagonal line, indicating an accurate assessment of significance
for AIM. We also generated Q-Q plots for dependent factors and unbalanced factor combinations.
Indeed, we have simulated the dependent factors with correlation coefficient as large as 0.9. We
also made one of the four factor combinations as small as 1 %. We do not observe any obvious
deviation from the diagonal line for these Q-Q plots.
3.1.1 Varying case fractions
Figure 2 shows the empirical type I error (evaluated when the null hypothesis of no interaction
is valid) at significance level 0.05. The gray region is the 95% confidence interval. We assessed
the influence of the case fraction on the empirical type I error. Each estimate is based on 1000
tests, with the empirical type I error calculated as the ratio between the number of tests that have
p-value smaller than 0.05 and the total number of tests. The AIM model used to generate the data
here is: log(1 − P (C = 1|x)) = a(−0.337 − 0.336x1 − 0.336x2), with a varied to sweep the range
of case fractions from 0.05 to 0.95. The factor distribution is the same as assumed for Figure 1
experiments. We can see that for all scenarios the empirical type I error closely approximates the
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Figure 1: Q-Q plot for AIM.
expected type I error.
3.1.2 Missing factors
Figures 3a, 3b, and 3c show the empirical type I error rate at significance level 0.05 for LR and
AIM. For each comparison, the left (dark) bar is LR’s measure and the right (light) bar is AIM’s.
This is the convention used in all our type 1 error figures. For AIM experiments, the data was
generated according to the baseline AIM model, and for LR experiments, the data was generated
according to the baseline LR model, with the ground-truth AIM and LR model parameter values
chosen so that the marginal effects of each of the factors was the same for the two (AIM and LR)
baseline models. We simulated in total 18 scenarios with different case fractions and number of
missing factors. To get reliable estimates of type I error, 10,000 datasets were simulated for each
scenario. Both the point estimate and the 95% confidence interval are shown in the figure. All the
scenarios are designed to have marginal effects with an odds ratio of 2 for the observable factors.
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Figure 2: Empirical type I error of AIM with varying case fraction.
In Figure 3a, we simulated one missing factor with effect size of 15. In Figure 3b, we simulated 10
missing factors with comparable effect sizes as for the observable factors. In Figure 3c we simulated
100 missing factors with effect sizes of 1.1. In all scenarios, the empirical type I error rates for AIM
match the theoretical value (0.05) very well. The inflation of type I error rate for LR has multiple
causes. However, generally speaking, the fewer number and the larger effect sizes of missing factors
result in larger inflation. Also seen from the figure, larger inflation occurs when the case-control
ratio deviates from balanced (0.5). Interestingly, we observed no inflation for LR when the case
fraction is 0.5.
3.1.3 Surrogate markers
Figures 4a and 4b compare the empirical type I error rates for both LR and AIM when the observed
markers are surrogate instead of causal. Each empirical type I error rate is estimated based on
10000 experiments. The dashed lines indicate the expected type I error rate and the 95% confidence
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(a) Few missing factors (b) Moderate missing factors (c) Many missing factors
Figure 3: Empirical type I error rate at significance level 0.05 for LR (dark grey) and AIM
(light grey) when there are a) a few missing factors with large effect size; b) a moderate
number of missing factors with moderate effect size; and c) when there are a lot of missing
factors with small effect size.
(a) Weak marginal effects (b) Strong marginal effects
Figure 4: Empirical type I error rate at significance level 0.05 for LR (dark grey) and AIM
(light grey) when the surrogate markers have a) weak marginal effects and b) strong marginal
effects; r2 is the correlation between a surrogate factor and its associated causal factor.
intervals for each estimate are marked by the corresponding error bars. In Figure 4a, the effect
size for the observable surrogate markers is small and approximately 1.5 in terms of odds ratio. In
Figure 4b, the effect size is around 5. The empirical type I error for AIM is close to the expected in
all cases. The accuracy of type I error rate for LR is dependent on two factors – the effect size and
the degree of correlation between a surrogate and its associated causal factor (r2). Larger effect
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size and weaker correlation generally imply larger deviation from the expected value.
(a) 3 subtypes (b) 20 subtypes
Figure 5: Empirical type I error rate at significance level 0.05 for LR (dark grey) and AIM
(light grey) when there are a) 3 subtypes and b) 20 subtypes. Odds ratio refers to the
marginal effect.
3.1.4 Subtypes
Figures 5a and 5b show the empirical type I errors when there are subtypes. We simulated four
scenarios with different effect sizes and number of subtypes. Here we assume both risk factors have
the same marginal effect size. When the effect size is large, the overall distribution deviates from
the null logistic regression model significantly, though each subtype follows the logistic regression
model. Each subtype independently generates the status of case or control, with the overall status
a ‘case’ if either subtype status is a ‘case’. We also notice that when the effect size is weak (odds
ratio = 1.5), the effect of the subtypes is negligible.
3.1.5 Impact of the violation of the independence assumption in Theorems 1
and 2
The simulations in Subsections 3.1.2 and 3.1.3 confirm Theorems 1 and 2 under independence
between the observable factors (when missing factors exist) or the causal factors (when surrogate
factors are observed). These assumptions are non-trivial. Here, we investigate numerically the
scenarios where the independence assumptions are violated. Our experiments show different effects
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of the violation of the assumption for the two theorems. Though we cannot prove it theoretically, it
seems that Theorem 1 still practically holds even when the observed factors are strongly correlated.
On the other hand, we do observe that the violation of the independence assumption leads to a
systematic, though often small, breakdown of Theorem 2. Note that Theorem 3 does not involve
the independence assumption and is not investigated here.
To test the impact of the violation of the independence assumption when missing factors exist,
we tried various settings as in section 3.1.2. We do not see obvious inflation of the type I error for
AIM. Based on our experience with LR, we hypothesized that the setting of a few but large-effect
missing factors is the one that is most likely to demonstrate the impact. The left subfigure in
Figure 6 shows the empirical type I error rate under this setting. Using an interval of 0.1, we
surveyed the correlation with coefficients ranging from -0.9 to 0.9. For all 19 sets of experiments,
all but r=0.2 have the expected Type I error rate falling in the 95% confidence interval. However,
the only exception should also be expected due to the effect of multiple tests. In fact, we fixed
r=0.2 and conducted the experiment again. This time, the expected type 1 error rate is within
the 95% confidence interval. We tried multiple settings as in section 3.1.3 to test the impact of
the violation on the type I error rate when surrogate factors are measured. Although for the
majority of the settings the effect is not detectable, a small fraction of settings consistently show
inflated type I error. The right figure of Figure 6 illustrates the effect under a typical scenario. The
correlation is 0.8 between the causal and surrogate factors. The inflation becomes obvious when
the correlation between the two causal factors is very strong. We do not see observable inflation
for moderate correlations. To further test whether the inflation is due to some random effect,
we fixed the correlation at 0.9 and increased the number of simulations to 100,000 to narrow the
confidence interval of the estimated type I error rate. We got a point estimate as 0.0615 and the
95% confidence interval is [0.0599, 0.0630].
3.2 Power comparison on synthetic datasets
In this section we report results on various synthetic datasets to assess the performance of AIM in
detecting true interaction effects. A comprehensive set of scenarios were simulated to evaluate how
the power of AIM is affected by sample size, effect size, case-control ratio, risk factor allele frequency,
p-value threshold, main effects, correlation between risk factors, missing factors, surrogate factors,
and disease subtypes. For every experiment, the performance of LR was also evaluated, with special
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Figure 6: Empirical type I error rate at significance level 0.05 for AIM when the independence
assumptions in Theorems 1 and 2 are violated. The left and right figures demonstrate the
scenarios for Theorem 1 (missing factors) and Theorem 2 (surrogate factors), respectively.
Red-dashed lines indicate the 95 % confidence interval.
attention paid to the different trends observed for AIM and LR. In all of the reported experiments,
power was empirically estimated based on 1000 random simulations. When we investigated the
effect of one parameter, we fixed all other parameters. The default p-value threshold (alpha value)
was set as 0.05. By default, we assumed risk factors are independent. In most of the experiments,
the interaction models were based on a logistic regression model with non-zero interaction terms,
as follows: log( p1−p) = β0 + β1x1 + β2x2 + β3x1x2. Here, both risk factors are binary. The odds
ratio is used to represent the effect size. Thus, eβ1 and eβ2 are the two main effect sizes and eβ3
the interaction effect size. By default, we set the main effect size for both risk factors to 1.5.
The interaction effect size was also set to 1.5. The risk allele frequency, that is, the frequency of
xi = 1, i = 1, 2 was set to 50%; β0 was adjusted so that the case fraction was around 50%. We
had two different default settings for the sample size. When the experiment assesses the impact of
interaction effect size, the sample size was set to 1000; otherwise the sample size was set to 2000. The
smaller sample size was designed to survey the impact of a larger range of interaction effect sizes.
The above-described interaction model was also extended to include high-order interactions and
more complex interaction forms. We took advantage of existing interaction models (Li(2011)) and
applied both AIM and LR to them. Specifically, five more interaction models were tested, spanning
from 2-way to 5-way interactions and involving ternary variables. In the following subsections we
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give detailed discussion on the results for each set of experiments; finally we summarize our overall
conclusions.
3.2.1 Impact of sample size and effect size
Figures 7a, b, and c show how power is affected by sample size with the interaction effect size fixed
at 1.1, 1.5, and 3, respectively. Figure 8 shows how power is affected by effect size with the sample
size fixed at 1000. As expected, for both methods the power increases from 0 to 1 when either the
sample size or the effect size is increased. We can also see that the effect size has more dramatic
impact on power than the sample size. For AIM, 1600 samples are needed to achieve 80% power
when the effect size is 1.5, compared to 280 samples when the effect size is doubled to 3.0. Under
all scenarios AIM is always better powered than LR. However, the difference in power is dependent
on the effect size. For example, in Figure 7a, to achieve 80% power, 13,000 and 57,000 samples
are needed for AIM and LR, respectively. In Figure 7b, when the effect size is 1.5, to achieve
80% power 1,600 and 3,200 samples are needed for AIM and LR, respectively. Generally speaking,
the relative gain of AIM over LR is larger for smaller effect sizes and for (relatively) small sample
sizes at a given effect size, as seen in Figures 7a,b,c. This is encouraging because one often faces
problems with small effect size (and limited sample size) in real applications. However, we can also
observe that the maximum gain in power of AIM over LR over the range of sample sizes (as well
as the area between the two power curves) decreases as the effect size increases.
(a) Small interaction effect size (b) Moderate interaction effect
size
(c) Large interaction effect size
Figure 7: Power vs sample size when the interaction effect size is fixed at a) an odds ratio of
1.1; b) an odds ratio of 1.5; c) an odds ratio of 3. The case fraction was 50% and the main
effect size was 1.5 for both risk factors.
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Figure 8: Power versus interaction effect size. The sample size is fixed at 1000. The main
effect sizes for both risk factors were set at the odds ratio of 1.5. The case fraction is fixed
at 50%.
3.2.2 Impact of case-control ratio
Figure 9 illustrates how the case-control ratio influences the power and how the two methods differ.
We surveyed the fraction of cases from the very low end (0.1) to the very high end (0.9). It should
be expected that power will not achieve its maximum at either end. Indeed, when the cohort is
composed of all cases or controls, there is no way to evaluate the difference between cases and
controls. Thus, the maximum power should be achieved at some intermediate value. Recalling
that logistic regression is a symmetric approach with respect to case/control status, it is reassuring
to see that logistic regression gets maximum power at a case fraction of 0.5. A striking difference
here is that AIM achieves its maximum power when the fraction of cases is around 0.3. We can
also observe that the gain of AIM over LR is larger when the fraction of cases is smaller. This
phenomenon is rooted in the defining formulas for AIM and LR. Comparing the AIM form log(1−p)
to the LR form log(p)− log(1− p), where p is the probability of a case, we can see that, neglecting
the sign, the two forms get close when p approaches 1.
3.2.3 Impact of risk allele frequency
Figure 10 shows how the risk allele frequency impacts power. The allele frequencies were simulated
to range from 0.1 to 0.9. The power is decreased for both AIM and LR when the risk allele
frequency is either extremely low or high. The power for LR is symmetric with respect to the
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Figure 9: Power versus case-control ratio. The fraction of cases is varied by adjusting the
baseline parameter β0 in the logistic regression model possessing an interaction term. The
sample size is 2000 and the interaction effect size is 1.5. The main effect sizes for both risk
factors are 1.5.
risk allele frequency, achieving its maximum at 0.5. The power curve for AIM is skewed to the
higher frequencies – when the risk allele frequency is 0.1, AIM has power of 0.4; when the risk allele
frequency is 0.9, the power is 0.55. Considering that we used 1000 simulations to calculate power,
this difference is highly unlikely to be due to random fluctuations. We do not have an analytical
characterization of how the risk allele frequency asymmetrically affects AIM’s power, with the
higher allele frequencies more power-favorable. However, we believe this is again a consequence of
the asymmetry of AIM with respect to case/control status.
3.2.4 Impact of main effect size
Figure 11 demonstrates how the main effect size affects the power to detect an interaction when
the interaction effect size is fixed. We observe that AIM and LR follow very different trends. LR’s
power slightly decreases as the main effect size increases. The power of LR is 0.352 at a main
effect size of 1.1 and reduces to 0.279 at a main effect size of 5.0. This decline in power is even
more apparent for larger main effect sizes. Although not shown in Figure 11, we observed that LR’s
power falls to 0.16 for a main effect size of 20. These results are not surprising – with the interaction
effect size fixed, the increase in main effect size increases the variance of the estimate of interaction
effect size. On the other hand, AIM’s power increases as the main effect size is increased. This
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Figure 10: Power versus frequency of risk allele. The sample size is 2000. The main effect
sizes for both risk factors are set as 1.5 and the interaction effect size is 1.5. In the experiments
one risk factor has the allele frequency changing while the other risk factor’s allele frequency
is fixed. The case fraction is fixed at 50%.
can be understood by recognizing i) that the interaction effect is the difference between the true
effect and the one predicted by the null hypothesis; and ii) that AIM and LR posit very different
null hypotheses. In particular, in this experiment the data were generated based on an LR model,
with the interaction effect size fixed while varying the main effect size. A fixed interaction effect
for an LR model will almost assuredly give a variable interaction effect size for the AIM model, as
the main effect size is varied.
3.2.5 Impact of p-value threshold
Figure 12 shows how the sample size needed for 80% power is dependent on the p-value threshold
of significance. We varied the p-value threshold from 0.05 to 5e-8. It appears that the sample size
is linearly proportional to the log-transformation of the p-value threshold, for both AIM and LR.
However, AIM’s slope is smaller than that of LR. When the p-value threshold is 0.05, 1600 and
3200 samples are needed for AIM and LR, respectively, i.e., twice AIM’s number of samples are
needed for LR. When the p-value threshold is 5e-8, the ratio is 2.17 (computed as 165,000 divided
by 76,000).
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Figure 11: Power vs main effect size. The sample size is 1000 and the interaction effect size
is fixed at 1.5. The case fraction is fixed at 50%.
Figure 12: Sample size versus p-value threshold. The main effect size is 1.5. The interaction
effect size is 1.5. The case fraction is 50%.
3.2.6 Impact of correlation between risk factors
Figure 13 illustrates how the correlation between the two risk factors affects power. High absolute
correlation significantly reduces power. For example, when the correlation is -0.95, the power
for AIM reduces from 0.902 to 0.282, while the power for LR reduces from 0.626 to 0.153. The
maximum power is achieved for both AIM and LR when the two risk factors are independent. It
is worth noting that unlike for the case-control ratio and allele frequency, AIM’s power, similar to
LR’s, exhibits symmetric dependence on the correlation between the two factors.
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Figure 13: Power to detect an interaction versus correlation between the risk factors for AIM
and LR models. Both methods achieve their greatest detection power when risk factors are
uncorrelated.
3.2.7 Impact of missing risk factors
Figure 14a compares the power for AIM under the three scenarios of no missing factors, a few
strong missing factors, and many weak missing factors. A similar comparison for LR is shown in
Figure 14b. We simulated three strong and one hundred weak missing factors, but with the overall
effect designed to be the same.
(a) AIM under missing factors (b) LR under missing factors
Figure 14: Power estimated based on 1000 simulation data sets when there are no missing
factors, a few strong missing factors, or many weak missing factors for a) AIM and b) LR.
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From these figures we can see that the power does not change too much for both AIM and LR
when there are missing factors. The change is so small that we cannot draw definitive conclusions
from the two figures; however, the existence of a few strong missing factors does appear to decrease
the power. To further assess this, we simulated 10,000 datasets, focusing on an interaction effect
size of 1.5, with the results shown in Table 3.
No missing factors A few strong missing factors Many weak missing factors
AIM power 0.602 [0.692,0.611] 0.555 [0.545, 0.565] 0.604 [0.594, 0.614]
LR power 0.348 [0.338, 0.357] 0.317 [0.308,0.326] 0.347 [0.337, 0.356]
Table 3. Power comparison when there are missing factors. The interaction effect size was
fixed at 1.5. Power was estimated based on 10000 simulations. Confidence intervals (shown
in brackets) were computed using a binomial distribution.
The existence of a few strong missing factors indeed decreases power for both AIM and LR;
however, many weak missing factors did not have any observable effect on the power. Since missing
risk factors do not change the power much, it is expected that AIM will still be more powerful than
LR, which is confirmed by Figures 15a,b.
(a) Several strong factors missing (b) Many weak factors missing
Figure 15: Interaction detection power versus interaction odds ratio for AIM and LR models
when a) several strong non-interacting factors are missing and b) many weak non-interacting
factors are missing.
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3.2.8 Impact of surrogate factors
Figure 16 shows how power is affected when surrogate rather than causal risk factors are measured.
Surrogate factors have very large impact on the power for both AIM and LR. For example, the
power for AIM drops from 0.877 to 0.486 when surrogate factors with correlation coefficient of 0.8
to their causal counterparts are observed. Similarly, the power for LR drops from 0.607 to 0.278.
No matter how great the power decrease, we see that AIM’s power is always greater than LR’s. It
is also noteworthy that both AIM and LR are symmetric with respect to the correlation coefficient
between surrogate and causal factors.
Figure 16: Interaction detection power under the surrogate factors scenario, as a function of
the correlation between surrogate and causal factors, for AIM and LR models.
3.2.9 Impact of subtypes
Figures 17a,b illustrate how the existence of subtypes impacts the power for both AIM and LR.
When there are subtypes, the power for both AIM and LR are significantly increased. It seems
that the existence of subtypes make the interaction effect stronger. Even so, we see in Figure 18
that, even with subtypes, AIM has better power to detect the interaction effect than LR.
3.2.10 Power for an antagonistic interaction
Figure 19 shows how the power varies with interaction effect size for an interaction that is an-
tagonistic. For a logistic regression model with interaction terms, an antagonistic interaction is
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(a) AIM under subtypes (b) LR under subtypes
Figure 17: Interaction detection power versus interaction odds ratio for a) AIM and b) LR
models under the cases of no disease subtypes and three disease subtypes.
Figure 18: Interaction detection power when there are two disease subtypes, as a function
of interaction odds ratio, for AIM and LR models.
defined as one with an interaction coefficient β3 that is negative. Equivalently, it is such that the
effect size (odds ratio) is smaller than one. The experiments were conducted exactly as in Figure 8
except that the effect size here was set to the reciprocal of the value used to produce Figure 8. The
experimental results are consistent with the statement in our theorem, with the power for logistic
regression larger than that for AIM when the interaction is antagonistic. However, the reduction
in power for AIM relative to LR is quite small. Interestingly, we observe another asymmetric
characteristic of AIM through this experiment – logistic regression is symmetric with respect to
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the log-transformation of the odds ratio, while AIM is not. Indeed, the gain of AIM over LR for
synergistic interactions is much larger than the loss relative to LR for antagonistic ones.
Figure 19: Power of AIM and LR versus interaction effect size for an antagonistic interaction.
3.2.11 Experiments on five previous published interaction models
We have also evaluated power to detect interactions for a simulated genomics data set (Li(2011)),
derived from real single nucleotide polymorphism (SNP) study data, as part of the New York City
Cancer Control Project. The simulated population retained the basic patterns of linkage disequi-
librium, missing data, and allele frequencies observed in the original genome scan data. Multiple
interactions (five) simultaneously exist in the simulated population (reasonable, considering com-
plex disease mechanisms) and jointly decide the phenotype for each individual. The five interaction
models vary in interaction order (from two-way up to five-way), genetic models (dominant, reces-
sive, or additive), incomplete/complete penetrance, minor allele frequency, and marginal effects
size. The chosen models, specified in (Li(2011)), were motivated by complex genetic traits (such as
autoimmune diseases, diabetes, and arthritis) where there are multiple loci contributing to disease
risk and where there are both some relatively large interaction effects as well as more modest ones
(Li(2011)). We considered data sets with 1000 samples and 100 SNP variables. Fifteen of these
SNPs participate in the five interaction models, with the remaining SNPs having no ground-truth
association with the disease status. Figure 20 shows the statistical significance of each ground-
truth interaction model, as detected by the AIM and LR models. Note that AIM achieves smaller
p-values for all five models. Smaller p-values imply fewer data subjects are needed to detect an
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interaction at a minimum required level of significance.
Figure 20: Statistical significance (log p-values) of five ground-truth interactions, as detected
by the AIM and LR models.
3.3 Overall conclusions from power comparisons
Summarizing the previous discussions, we have the following overall conclusions on the power
comparisons: (1) For synergistic interactions, under all scenarios and parameter combinations,
AIM is always better powered than LR. (2) The power gain of AIM over LR is larger when the
interaction effect size is small and/or when the sample size is relatively small. (3) The power gain
of AIM over LR is larger when the main effect is large. (4) The power gain of AIM over LR is
larger for small case fractions, as opposed to large case fractions. (5) The existence of missing risk
factors, surrogate factors or subtypes may decrease or increase the power for both AIM and LR,
but AIM always has larger power than LR. (6) AIM is not only conceptually asymmetric (with
respect to disease status) – its power is also asymmetric, with respect to both the case-control ratio
and the allele frequency.
4 Experiments on Real Datasets
Interaction between ALDH2 gene and alcohol consumption on esophageal cancer
Both the ALDH2 gene and alcohol consumption are known factors associated with esophageal
cancer. Heavy alcohol consumption has been found to be a risk factor for esophageal cancer in many
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epidemiological studies (Allen(2009)). When alcohol is metabolized in the liver, it is broken down to
acetaldehyde, which is oxidative and recognized as a carcinogen by binding to cellular protein and
DNA. The majority (99%) of the produced acetaldehyde is eliminated by the liver. The ALDH2
protein is responsible for degrading the remaining carcinogen. There is a functional polymorphism
in the ALDH2 gene, namely ALDH2 Glu478Lys. The Glu allele encodes a protein with normal
catalytic activity, while the Lys allele encodes an inactive protein. A defect in the ALDH2 genes
significantly reduces the capacity to degrade acetaldehyde and hence exposes an individual to more
acetaldehyde than normal. It is biologically plausible for the ALDH2 protein and alcohol consump-
tion to interactingly influence the risk of esophageal cancer (Lewis(2005),Matsuo(2001)). Figure
21 shows the re-analysis of the interaction between the ALDH2 gene and alcohol consumption.
Figure 21: Re-analysis of the interaction between the ALDH2 gene and alcohol consumption.
The data was collected from the first study of the ALDH2-alcohol interaction effect on esophageal
cancer. The original report discovered the interaction effect via LR, which was confirmed by follow-
up studies (Lewis(2005)) to be a true interaction. The distribution of the cases and the controls are
presented in the figure. We re-analyze the data using AIM. The significance through our model is
7.4e-6, compared to a p-value of 2.5e-3 with LR, an almost thousand-fold improvement. There are
in total 343 subjects in the study. When all the frequencies of the risk factors and the effect size
are kept the same, we estimate that, to achieve the 0.05 significance level, LR requires 142 subjects
while AIM needs only 64 subjects.
Interaction between thrombophilic mutations and oral contraceptive on the venous
thrombosis
The interaction of thrombophilic mutations with oral contraceptives on venous thrombosis is
a pronounced example of a gene-environment interrelationship study. A venous thrombosis is a
blood clot that forms within a vein, especially in the deep veins of the legs or in the pelvic veins.
There are both genetic and environmental risk factors. The R506Q mutation of factor V and
the G20210A mutation of prothrombin are two thrombophilic genetic factors (Rosendaal(1999)),
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moderately common in whites with frequencies of 5% and 2%, respectively. Factor V is a protein
of the coagulation system and factor Va (activated factor V) is a highly procoagulant cofactor in
the generation of thrombin, which is a crucial element in blood clotting. The R506Q substitution
in factor V involves one of three sites that are cleaved by activated protein C. This mutation slows
down the proteolytic inactivation of factor Va, which in turn leads to the augmented generation
of thrombin (Seligsohn(2001)). Prothrombin is proteolytically cleaved to form thrombin. The
G20210A mutation in the 3’ untranslated region of the prothrombin gene is associated with an
increased level of plasma prothrombin, promoting the generation of thrombin and impairing the
inactivation of factor Va by activated protein C (Seligsohn(2001)). The use of oral contraceptives
has long been recognized as a risk factor for venous thrombosis. Oral contraceptive has significant
effect on the generation of thrombin, by both decreasing the level of factor V and increasing the
level of prothrombin.
The interaction between thrombophilic mutations and oral contraceptive is well-established,
with multiple epidemiological and mechanical studies (Legnani(2002), Martinelli(1999), Rosing(1999),
Vandenbroucke(1994)). Table 4 and Table 5 show two studies illustrating the interaction between
the thrombophilic genetic mutation and the use of oral contraceptive.
thrombophilic genetic risk 
mutation
oral contraceptive controls cases odds ratio
- - 444 118 1
- + 166 86 1.95
+ - 33 42 4.79
+ + 7 51 27.4
Table 4. Legnani et al. study: risk of venous thrombosis according to the presence of
thrombophilic genetic mutation and the use of oral contraceptive.
In the Legnani et al. study, the odds ratio associated with the use of oral contraceptive but no
thrombophilic genetic risk mutation is 1.95, and the odds ratio associated with genetic defects but
no use of contraceptive is 4.79. According to the multiplicative model, the odds ratio associated
with the presence of both risk factors should be 9.34, while the observed odds ratio is 27.4. This
is strong evidence of interaction. Indeed, by applying LR, we get a p-value of 0.021, which is
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thrombophilic genetic risk 
mutation
oral contraceptive controls cases odds ratio
- - 127 35 1
- + 41 52 4.60
+ - 7 5 2.59
+ + 4 20 18.1
Table 5. Martinelli et al. study: risk of venous thrombosis according to the presence of
thrombophilic genetic mutation and the use of oral contraceptive.
statistically significant. If we apply AIM, we get a p-value of 0.00062. There are 947 subjects in
the Legnani et al. study. When all the frequencies of the risk factors and the effect size are kept
the same, we estimate that, to achieve the 0.05 significance level, LR requires 676 subjects, while
AIM needs only 303 subjects.
For the Martinelli et al. study, the odds ratio associated with the presence of both risk factors
(according to a multiplicative model) is expected to be 11.9, compared to the observed value of
18.1. Both studies have the same effect direction, that is, the observed odds ratio is larger than
the expectation. Due to the limited sample size, the conclusion is not statistically significant in
the Martinelli et al. study. The p-value generated by LR is 0.618 and the p-value obtained from
AIM is 0.183. To achieve the 0.05 significance level, the estimated sample size associated with LR
is 4391, while AIM requires just 614 subjects.
Interaction between NAT2 gene and smoking on bladder cancer
With hundreds of thousands of new cases diagnosed each year worldwide, bladder cancer is
increasingly important for public health, with tobacco smoking the predominant known risk factor.
In Europe, smoking is estimated to cause over half of bladder cancer cases in men and one-third of
cases among women (Zeegers(2000)). Multiple carcinogens have been found in tobacco smoke, in-
cluding polycyclic aromatic hydrocarbons, N-nitrosamines, aromatic amines, heterocyclic amines,
and aldehydes. Originally inert, these carcinogens may undergo both activation and detoxifica-
tion. Imbalance between activation and detoxification will increase the bladder cancer risk through
accumulation of active carcinogen metabolites and increased DNA adduct formation (Gu(2005)).
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The NAT2 gene encodes an enzyme that functions to both activate and deactivate arylamine
and hydrazine drugs and carcinogens (Sanderson(2007)). The NAT2 enzyme is particularly active
in the liver, gastrointestinal tract, and urinary bladder, among other organs and tissues. Due to
the metabolic rate of exogenous compounds, the polymorphisms in the NAT2 gene can be classified
into two types – rapid acetylator and slow acetylator. NAT2 slow acetylator is very common in the
Caucasian population, estimated to be around 55%. The association of the NAT2 slow acetylator
with bladder risk is quite well established, serving as an outstanding example prior to the GWAS
era for the replicated association between common genetic polymorphisms and complex diseases.
Multiple studies have consistently shown the interaction between the NAT2 gene and smoking on
bladder cancer (Garcia-Closas(2005),Gu(2005),Sanderson(2007)). Table 6 presents the non-meta-
analysis study with the largest sample size (Garcia-Closas(2005)). Choosing the bladder cancer
risk for “never smoked” and NAT2 fast acetylator as the reference, the odds ratio associated with
“smoked before” (i.e., an individual who has smoked before) and NAT2 fast acetylator is 1.86, and
the odds ratio associated with “never smoked” and NAT2 slow acetylator is 0.91. According to
the multiplicative model, the odds ratio associated with the presence of both risk factors should
be 1.69, while the observed odds ratio is 2.89. So the interaction is evident. Indeed, by applying
LR, we get a p-value of 0.015. When we apply AIM, we get a p-value of 0.0011. There are 2264
subjects in the study. When all the frequencies of the risk factors and the effect size are kept the
same, we estimate that, to achieve the 0.05 significance level, LR requires 1449 subjects and AIM
needs 796 subjects.
NAT2 acetylation genotype smoking status controls cases odds ratio
Fast never 131 66 1
Fast ever 362 340 1.86
Slow never 199 91 0.91
Slow ever 438 637 2.89
Table 6. Joint association of tobacco smoking status and NAT2 acetylation genotype with
bladder cancer risk.
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Interaction between tobacco smoking and alcohol drinking on esophageal cancer
It has long been suggested that tobacco smoking and alcohol consumption interplay to influence
the risk of cancer (Garro(1990)). Alcohol may act as a cocarcinogen and enhance the carcino-
genic effects of other chemicals from tobacco smoking. Indeed, quite a few epidemiological studies
have confirmed their interaction effect on esophageal cancer (Castellsague(1999),Lee(2005)). The
Castellsague et al. report (Castellsague(1999)) is probably the first large scale case-control study
implying the interaction effect of tobacco smoking and alcohol consumption on esophageal cancer.
The study showed that the combination of the two factors significantly increased disease risk more
than either of them separately. However, although the report demonstrated statistical evidence for
both the female group and the all subjects group, it failed to find a significant interaction in the
male group. By applying the new model (AIM), interaction analysis generates consistent results.
Table 7 presents the subject distribution specified by the status of alcohol drinking, tobacco smok-
ing and esophageal cancer in the Castellsague et al. study. The data are divided into three groups
– males, females, and all subjects. In each group, we calculate the interaction effect based on LR
and AIM. We can see that the new model consistently generates smaller p-values than LR. In the
males group, the p-value is 5.43e-6 based on the new model, while it is 0.81 for LR and far from
being considered as significant. We also estimate the sample sizes required for the two models to
achieve the 0.05 significance level, again assuming that all the frequencies of the risk factors and
the effect size are kept the same. In the males group, LR needs 131413 subjects, compared to 374
subjects required for AIM. In the females group, LR needs 339 subjects and AIM needs 235. In
the all group, 596 subjects are necessary for LR , while 312 subjects are sufficient for AIM.
Summary of results on real data sets:
1. On esophageal cancer, we re-analyzed the established interaction between ALDH2 gene and
alcohol consumption with a more convincing p-value 7.4e-6, compared to 0.0025 for logistic
regression. The sample size required for good power is reduced from 142 to 64. [Reanalysis
: more convincing statistical evidence, gene-environment interaction]
2. On venous thrombosis, we re-analyzed the established interaction between thrombophilic
mutations and oral contraceptive with a more convincing p-value 0.00062, compared to 0.021
for logistic regression. The sample size required for good power is reduced from 676 to 303.
[Reanalysis : more convincing statistical evidence, gene-environment interaction]
3. On bladder cancer, we re-analyze the established interaction between NAT2 gene and smok-
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alcohol smoking 
males females all
control
s cases
odds 
ratio
control
s cases
odds 
ratio
control
s cases
odds 
ratio
never never 189 8 1 234 83 1 423 91 1
never ever 298 61 4.84 55 27 1.38 353 88 1.16
ever never 144 24 3.94 63 29 1.30 207 53 1.19
ever ever 777 562 17.1 19 36 5.34 796 598 3.49
Logistic regression 
(p) 0.81 0.014 5.10e-5
Log regression (p) 5.43e-6 0.0031 2.11e-8
Table 7. Joint association of alcohol drinking and tobacco smoking statuses with esophageal
cancer risk.
ing, with a more convincing p-value 0.0011, compared to 0.015 through logistic regression.
The sample size required for good power is reduced from 1,449 to 796. [Reanalysis : more
convincing statistical evidence, gene-environment interaction]
4. On environment-environment interaction between tobacco smoking and alcohol drinking on
esophageal cancer, we re-analyzed the data, eliminating originally conflicting/inconsistent
results. [Reanalysis : eliminating inconsistency, environment-environment interaction]
5. Across all of our real data set experiments, AIM demonstrated enhanced power compared to
LR. We further checked the types of interactions and found that they are all synergistic – in
all of these applications, carrying double risk factors engendered larger risk than expected
from any individual risk factor. These experimental results thus corroborate our Theorem 4
on the comparison of power.
5 Related Work and Discussion
Identification of statistical interactions between participating factors has many practical implica-
tions. For instance, significant efforts have been made to investigate gene-environment interactions,
as it is well accepted that multiple genetic and environmental factors acting in interconnected bi-
ological pathways or networks contribute to the susceptibility and progression of complex human
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diseases. Besides revealing the mechanisms underpinning the disease, the identification of gene-
environment interactions may assist the design of targeted therapies, interventions, or preventive
strategies for complex diseases. After all, the genetic variants that are most easily translated for
public health or clinical utility will be those that have an obvious corresponding environmental mod-
ification identified to be capable of altering the disease risk. In contrast to the impressive accumula-
tion of data resources due to the successful launch of GWAS during the past five years, the progress
on analytical approaches has been limited, with LR still the de facto standard (Cordell(2009)). De-
spite its popularity, LR occasionally receives critiques, albeit mainly for its lack of power or due to
its excessively large required sample sizes. However, the fundamental problems we have discussed
in this paper have received little attention. Various efforts have been made to enhance LR’s power.
One major school is based on the case-only study (Cordell(2009)). Under two assumptions – (1)
the two risk factors are independent in the population and (2) the disease incidence rate is rare –
it can be shown that LR for interaction analysis reduces to association analysis between the two
risk factors in the case group only. Simulation studies have demonstrated larger power of case-only
studies compared to LR. However, it was pointed out that the power gain was purely owing to
these strong assumptions, since, under them, fewer parameters need to be estimated and the true
interaction effect can be more easily distinguished from the null distribution with fewer degrees
of freedom. Yet, in real applications, these assumptions may not hold. A gene may influence the
environment to which an individual is exposed. For example, genetic makeup may be a strong de-
terminant of lifestyle. Even for some seemingly unlikely dependency, the independence assumption
can be violated indirectly, for instance, through family history. For example, a potential inheritor
of the BRCA1 gene may tend to opt for oral contraceptives because of the history of breast cancer
in the family. Violation of the independence assumption often leads to inflated false positive rates.
Sometimes it will also result in decreased power. (Wu(2011)) provides such an empirical exam-
ple. The case-only method missed the interaction between the ALDH2 gene and drinking status
on esophageal squamous-cell carcinoma, whereas standard LR successfully detected it, because a
person with the risk allele in the ALDH2 gene tends to not drink due to the flushing reaction while
drinking.
New variants of the case-only method, including empirical Bayes (Mukherjee(2008)) and model
averaging (Li(2009)), were proposed to combine the strengths of the case-only study and of LR,
aiming at gaining power by exploiting the assumption of independence and yet protecting against
false positives when the independence assumption is violated. However, these methods are essen-
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tially weighted averages of the case-only and case-control statistics, and hence they are necessarily
liberal under the violation of the independence assumption. At the same time, case-only and its
variants will be invalid for common diseases like diabetes or heart diseases due to the violation of
the assumption of rare incidence. More importantly, both the case-only method and its variants
share the same principle with LR, that is, that null models be multiplicative for disease risks coming
from multiple factors. Therefore, the fundamental problems we discussed pertaining to LR also
apply to the case-only method and its variants.
All the approaches discussed above – LR, the case-only method, and its variants – can be
considered multiplicative models because their null hypotheses all posit a product of disease risks
when all risk factors are present. An alternative is the so-called additive model, which hypothesizes
an additive effect of disease risks when multiple risk factors are present. This model was highly
motivated by the public health goal of finding cost-effective intervention strategies for disease
reduction, since departures from additive risk would identify special groups that benefit most from
a given intervention. On the one hand, an interaction relevant to the public health goal is not
necessarily the most biologically meaningful. On the other hand, we do realize that the additive
model can be derived as a special case of AIM if we assume the phenotype we are interested in,
that is, the case, has low prevalence in the population so that mathematically log(1 − p) ≈ −p.
Nonetheless, there are disease domains for which this approximation is wildly violated. One is
common diseases. For instance, according to the Centers for Disease Control and Prevention
(CDC), the prevalence of coronary heart disease is as high as 19.8% among persons ≥ 65 years in
2010. According to the American Diabetes Association, 11.3% of all people ≥ 20 years have diabetes
in 2011. If the population is restricted to those ≥ 65 years, the prevalence reaches 26.9%. It is
also highly likely that a rare disease becomes quite common when referring to a special population,
such as Finnish heritage disease. Another important scenario is where the interest of a study is on
the progression of the disease instead of its occurrence. Even though the incidence rate can be very
low, the poor prognosis group, which is often considered as the ‘cases’, can constitute any fraction
of the whole patient group.
6 Conclusions
We first considered the widely used logistic regression model, identifying its limitations as a plausible
model for disease risk. We further identified that logistic regression is not theoretically supported
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for hypothesis testing on statistical interactions between risk factors under the following common
scenarios: 1) when there are additional (unmeasured) risk factors; 2) when measured factors are
“surrogates”, imperfectly correlated with the true factors; 3) when there are multiple disease sub-
types. Alternatively, we proposed as the null the Asymmetric Independence Model (AIM) which:
i) crucially, unlike LR, is asymmetric with respect to “diseased” and “healthy” statuses; ii) more
generally, does comport with well-accepted biological models; and iii) whose mathematical form
is preserved under all of the above confounding scenarios. Finally, we gave a precise, operational
definition of a “synergistic” interaction, an interaction type commonly encountered in practice, for
which we proved mathematically that AIM has greater detection power than LR, irrespective of
whether the above confounding scenarios are active. Experiments evaluating AIM and LR both
on simulated data sets as well as on four real disease case-control study domains demonstrate
AIM’s improved detection power over LR. Moreover, controlled experiments demonstrate both the
inflated type 1 error of LR, and the type 1 error resilience and better detection power of AIM, under
unmeasured, surrogate factor, and disease subtype scenarios. Through simulation studies, we also
characterized how, for each of the two methods, power depends on an array of population variables
and experiment design parameters, including sample size, effect size, case-control ratio, risk factor
allele frequency, p-value threshold, main effects, correlation between risk factors, missing factors,
surrogate factors, and disease subtypes. Beyond observing that AIM achieved improved power over
LR under all the tested scenarios involving synergistic interactions, some of our interesting findings
include that: 1) The power gain of AIM over LR is larger when the interaction effect size is small
and/or when the sample size is relatively small; 2) The power gain of AIM over LR is larger when the
main effect is large; 3) Fitting to its name, AIM is not only conceptually asymmetric – its power is
also asymmetric, with respect to the case-control ratio, the allele frequency, and the log of the odds
ratio; 4) While LR does have a detection power advantage over AIM for antagonistic interactions,
we observed very modest power differences between the two models for the simulated antagonistic
interactions we investigated, for all tested interaction effect sizes. We also note that, in many
instances, it may be possible to determine the hypothesized interactions “direction” (synergistic or
antagonistic) and choose the null hypothesis model accordingly.
7 Supplementary
Appendix A: Model Inconsistency of LR in the Presence of Surrogate Risk Factors
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Consider an example where N = 2 and where, when both causal factors are observed, the baseline
LR model has parameters β0 = −4, β1 = 2, and β2 = 2. The corresponding disease distribution is
shown in Table 8.
p X2 = 0 X2 = 1
X1 = 0 0.0180 0.1192
X1 = 1 0.1192 0. 5000
Table 8. Posterior probability of disease with two causal SNPs X1 and X2 under the logistic
regression model.
However, suppose now that, rather than observing the causal factors X1 and X2, we observe
two surrogate factors, X ′1 and X ′2, correlated with their respective causal factors and statistically
independent of each other. Assume P (X ′m = 0|Xm = 0) = 0.9, P (X ′m = 1|Xm = 1) = 0.9, and let
P (Xm = 0) = 0.5,m = 1, 2.
Applying Bayes rule and using the fact, for this example, that P (X1 = i,X2 = j) = P (X
′
1 =
i′, X ′2 = j′) = 0.25, ∀i, j, i′, j′, we find that
PLR(C = 1|X ′1 = k1, X ′2 = k2) = (8)
1∑
i=0
1∑
j=0
PLR(C = 1|X1 = i,X2 = j)P (X ′1 = k1, X ′2 = k2|X1 = j,X2 = j).
The resulting disease distribution is shown in Table 9.
Now, assuming that the LR model form is preserved when the surrogate factors, rather than
the causal factors, are observed, let us denote by β′0, β′1, and β′2 the parameter values for the new
LR model. We can compute these based on Table 9, as follows:
β′0 = log
(
P (C = 1|X ′1 = 0, X ′2 = 0)
1− P (C = 1|X ′1 = 0, X ′2 = 0)
)
= log
(
0.0410
1− 0.0410
)
= −3.1523
β′1 = log
(
P (C = 1|X ′1 = 0, X ′2 = 1)
1− P (C = 1|X ′1 = 0, X ′2 = 1)
)
− β′0 = log
(
0.1444
1− 0.1444
)
+ 3.1523 = 1.3731
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p X2’ = 0 X2’ = 1
X1’ = 0 0.0410 0.1444
X1’ = 1 0.1444 0.4266
Table 9. Posterior probability of disease with two surrogate variables X ′1 and X
′
2 under the
logistic regression model.
β′2 = log
(
P (C = 1|X ′1 = 1, X ′2 = 0)
1− P (C = 1|X ′1 = 1, X ′2 = 0)
)
− β′0 = log
(
0.1444
1− 0.1444
)
+ 3.1523 = 1.3731
The odds for the genotype (X ′1 = 1, X ′2 = 1) based on this model is:
P (C = 1|X ′1 = 1, X ′2 = 1)
1− P (C = 1|X ′1 = 1, X ′2 = 1)
= eβ
′
0+2β
′
1 = 0.6662. (9)
However, from Table 9, the odds for (X ′1 = 1, X ′2 = 1) is
0.4266
1−0.4266 = 0.7440. Thus, the assump-
tion that the LR form is preserved when surrogate factors, rather than the true causal factors are
observed (that is, that the correlation structure between the causal and surrogate factors can be
accounted for while preserving the baseline LR model form) is contradicted in this example and,
thus, as a general rule.
Appendix B
Theorem 5: AIM’s log-likelihood function is concave in its model parameters.
Proof: The Hessian matrix of second order partial derivativesH = [∂2logL/∂βi∂βj ] = −
M∑
i=1
Iiwiyiy
T
i
,
where y
i
= [1 xi], Ii is an indicator with value 1 if subject i is a case and zero otherwise, and
wi = PAIM(C = 1|xi)/(1 − PAIM(C = 1|xi))2 > 0. A non-negatively weighted outer product
is non-negative definite, and a sum of non-negative definite matrices is also non-negative. Thus,
the Hessian matrix (with a negative sign out front) is non-positive definite. Further, assuming
the matrix is full rank, it is negative definite. Thus, the log-likelihood function is concave in its
parameters.
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Appendix C: Constrained Maximum Likelihood Algorithm for Estimating the AIM
Model
As shown in Appendix B, AIM’s log-likelihood objective function is concave in the param-
eters β. Since the linear constraints on these parameters form a convex feasible region in the
parameter space, constrained MLE of AIM’s model parameters amounts to a convex optimization
(Boyd(2003)), for which globally optimal parameter estimates (or those approximating the global
optimum to any required level of precision) can be efficiently found. In the sequel, we describe
the two-step algorithm (Boyd(2003)), based on use of Newton-Raphson as initialization and a log-
barrier interior point algorithm (Boyd(2003)) to refine the solution, which we used in producing
AIM MLE parameter estimates.
Assume M subjects, with Ii = 1 indicating the i-th subject is a case and Ii = 0 indicating a
control. Define the augmented factor vector y = [1 xT ]. Thus, given the parameter vector β, the
class posterior log-likelihood over all M subjects (assuming subject independence) is:
L(β) =
M∑
i=1
(
(1− Ii)βT yi + Ii log(1− e
βT y
i)
)
. (10)
Maximum likelihood estimation for β is posed as:
arg max
β
L(β) subject to βT y
i
≤ 0, i = 1, . . . ,M. (11)
Note that even if M > 2N , the number of distinct constraints is upper-bounded by the number of
unique binary factor vectors, 2N .
Optimization Strategy:
An important empirical observation is that, frequently, the solution to the unconstrained problem
(obtained by ignoring the constraints in (11)) in fact satisfies all the constraints. We thus propose
a two-stage optimization exploiting this to achieve computational efficiency in practice. In the
first stage, Newton-Raphson is used to solve the unconstrained MLE problem, albeit with a check
on constraint satisfaction after each iteration. If any constraint is violated, we terminate this
stage and go to the second stage; otherwise, Newton-Raphson iterations are applied until the
specified convergence target is met. In the provisional second stage, we apply the log-barrier
method (Boyd(2003)) to solve the constrained problem. The basic idea is to define a penalized log-
likelihood function that leaves the log-likelihood unmodified when there are no constraint violations
but severely penalizes any violations. The penalty function thus acts as a “barrier”, ensuring
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the parameter vector always remains feasible while iteratively maximizing the penalized objective
starting from the interior of the feasible region. Since the penalty function described above is
not in general differentiable, we instead construct a differentiable surrogate penalty, indexed by a
parameter t, that approaches the desired penalty in the limit as t→∞. The modified penalized log-
likelihood (based on the surrogate penalty) is maximized for an increasing sequence of parameter
values t(0), t(1), t(2), . . . via a continuation method, i.e. with the solution for the objective indexed by
t(i) used as initialization for t(i+1). From the duality theory of convex optimization (Boyd(2003)),
one can strictly bound the log-likelihood deficiency of the current solution (with respect to the
global maximum log-likelihood), which inversely depends on t. Thus, one can achieve any desired
precision to the global maximum by optimizing for t sufficiently large. This log-barrier approach
is described in detail in (Boyd(2003)). Below, we summarize the main algorithm steps.
First stage: Newton-Raphson to solve the unconstrained problem
Given the current estimate β(k), the next estimate β(k+1) is produced by: β(k+1) = β(k)−H(β(k))∇βL(β(k)),
where H(·) is the Hessian matrix:
H(β) =
M∑
i=1
IiPAIM(C = 1|xi;β)/(1− PAIM(C = 1|xi;β))2yiyTi (12)
and
∇βL(β) =
M∑
i=1
(1− Ii)yi + IiPAIM(C = 1|xi;β)/(1− PAIM(C = 1|xi;β))yiyTi . (13)
The Newton method has a quadratic convergence rate. It usually converges in less than 10 iterations
in our application.
Second stage: Barrier method to solve the constrained problem
Letting I+(x) = 0 if x > 0 and ∞ otherwise, the preceding constrained optimization problem is
equivalent to: maxβ L(β) +
M∑
i=1
I+(−βT yi). Note that the optimum must occur for β satisfying
βT y
i
< 0, i = 1, . . . ,M to avoid the infinite penalty. Moreover, in this (feasible) case, the penalized
log-likelihood reduces to the pure log-likelihood. Since I+(x) is not differentiable, we substitute the
following penalty function that approaches I+(x) in the limit of large t: φt(x) =
1
t log(x) for x > 0
and ∞ otherwise. For given t, we thus solve: maxβ L(β) +
M∑
i=1
φt(−βT yi). Note that this objective
function is also concave. Thus, for each t, we can apply the Newton method for its maximization.
As t→∞, this modified problem approaches the original problem.
Schedule for t and choice of t(0):
The control parameter is updated using an exponential schedule: t(k+1) = λt(k), λ > 1. As
discussed in (Boyd(2003)), a reasonable choice for t(0) is such that M/t(0) is approximately λ(L∗−
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L(β(0)), where L∗ is the true maximum. Since L∗ and L(β(0)) are both unknown, we approximate
their difference by the log-likelihood difference between the last two Newton iterations in stage 1
(immediately prior to detecting constraint infeasibility).
While large λ reduces the number of optimizations performed in reaching a target value tfinal, a
“too large” difference (t(k+1) − t(k)) may mean that the solution at step k gives poor initialization
at step k + 1, translating to slow convergence of the Newton algorithm. There is thus a tradeoff
in the choice of λ. Experiments suggest that values in the range [3, 100] are reasonable choices. In
our experiments we set λ = 20.
Parameter Choices:
For the inner loop (Newton minimization), we stop if the increase in log-likelihood is less than
10−6. For the outer loop (over t), we stop if t(k) > 106M . From the dual optimization theory
(Boyd(2003)), this ensures a log-likelihood deficiency of less than 10−6.
Appendix D: Proof of AIM’s Consistency Under Missing Factors
Suppose that the N factors Xi, i = 1, . . . , N , each with discrete range denoted R(Xi), are statisti-
cally independent and that, given all factors observed, the disease status is generated according to
the AIM posterior PAIM(C = 1|x) = 1−P (C = 0|x) = 1− e
β0+
N∑
i=1
βixi
, where β0 will be referred to
as the background parameter. We prove that the posterior on disease status remains of this form
when only a subset of the factors are observed. Let S ⊂ {1, 2, . . . , N} be the indexes of the ob-
served factors. We thus show that, for any S, log(1−P (C = 1|x)) = e
β′0+
∑
i∈S
β′ixi
, where, moreover,
β′i = βi, i ∈ S.
Let Sj be any subset of cardinality N − j. The proof is by induction on j. First, note that
S0 = {1, 2, . . . , N} and, since by assumption the posterior is the AIM model when all factors are
observed, for S0 the posterior is indeed of the AIM form, with β′i = βi, i = 1, . . . , N and β′0 = β0.
Thus, the results holds at j = 0. Next, assume that the result holds for any subset of size j,
Sj = {i1, i2, . . . , ij}. That is, the posterior on disease status, given observation of the factors in the
subset Sj , is of the AIM form, with unperturbed parameter values β′i = βi, i ∈ Sj . Let us denote
the background parameter value in this posterior by β˜0. We must show consequentially the result
also holds for the subsets Sj+1. Note that if we remove one factor from any subset Sj , we obtain a
subset Sj+1. We can express the posterior for this subset by:
P [C = 0|xi1 , xi2 , . . . , xij−1 ] (14)
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=
∑
xij∈R(Xij )
P [C = 0, xij |xi1 , xi2 , . . . , xij−1 ]
=
∑
xij∈R(Xij )
P [C = 0|xi1 , xi2 , . . . , xij−1 , xij ]P [Xij = xij |xi1 , xi2 , . . . , xij−1 ]
=
∑
xij∈R(Xij )
P [C = 0|xi1 , xi2 , . . . , xij−1 , xij ]P [Xij = xij ]
=
∑
xij∈R(Xij )
(1− e
β˜0+
j∑
l=1
βilxil
)P [Xij = xij ]
= 1− e
β˜0+
j−1∑
l=1
βilxil
(
∑
xij∈R(Xij )
eβijxijP [Xij = xij ]).
That is the posterior’s form is preserved, with β′il = βil , il ∈ Sj+1 and where we identify the new
background parameter, with no dependence on any of the factors, as β′0 = β˜0+log(
∑
xij∈R(Xij )
eβijxijP [Xij =
xij ]).
Q.E.D.
Appendix E: Proof of AIM’s Consistency Under Surrogate Factors
Suppose there are N true disease factors Xi, each with discrete range space R(Xi), i = 1, . . . , N ,
and with one special value of the range space, denoted vi, corresponding to the disease factor not
being active1. Suppose that, when all N factors are observed, the disease status posterior has the
AIM form:
log(1− P (C = 1|x1, x2, . . . , xN )) = β0 +
N∑
i=1
βi(xi), (15)
where if xi = vi, βi(xi) = 0, ∀i. Now suppose that there is a subset of factors which are not
observed. However, rather than being missing, surrogate factors, correlated with these true factors,
are observed. Let X ′i denote the observed surrogate factor correlated with true factor Xi. Assume
each true factor Xi is conditionally independent of all other factors (true or surrogate) given its
surrogate X ′i. Further, assume that the disease status is conditionally independent of a surrogate
factor given its true factor. Under these assumptions, we prove that the posterior probability on
disease status, given all observed factors (both true and surrogate factors) remains of the AIM
1Here we are allowing each factor to have a non-binary range space. In the case of binary factors,
consistent with the derivation of the AIM model in the main paper, the value indicating a factor’s inactivity
is vi = 0. More generally, for non-binary factors, we are supposing there is a value vi indicative of a factor’s
inactivity.
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form and, moreover, is such that, for a true observed factor Xi = xi, its parameter value is
βi(xi)∀xi ∈ R(Xi), that is the parameter value is unaltered by the presence of surrogate factors.
Let Sj = {i1, i2, . . . , ij} be any subset of surrogate factors, of cardinality j, with companion
set S¯j = {l1, l2, . . . , lN−j}. The proof is by induction on j. First, note that S0 = {}, with all true
factors observed. Since by assumption the posterior in this case has the AIM form with parameter
values βi, i = 1, . . . , N , the result holds for j = 0. Next, assume that the result holds for some
j > 0, i.e. for the subsets Sj . That is, given j observed surrogate factors and N − j observed true
factors, the posterior form is the AIM form, where, further, for each true factor value Xi = xi, its
parameter value is βi(xi), i.e. the same value as when no observed factors are surrogates. Denoting
the set of parameter values for a surrogate factor X ′i by β′i(ω), ω ∈ R(X ′i), the posterior form for
any surrogate factor subset Sj is thus:
log(1− P (C = 1|x′i1 , x′i2 , . . . , x′ij , xl1 , xl2 , . . . , xlN−j )) = (16)
β˜0 +
j∑
m=1
β′im(x
′
im) +
N−j∑
n=1
βln(xln),
where β˜0 is the value of the background parameter (which will not in general equal β0).
We must show this result consequentially holds for the subsets Sj+1. The posterior for a subset
Sj+1 is:
P [C = 0|x′i1 , x′i2 , . . . , x′ij+1 , xl1 , xl2 , . . . , xlN−j−1 ] = (17)∑
xij+1∈R(Xij+1 )
P [C = 0, xij+1 |x′i1 , x′i2 , . . . , x′ij+1 , xl1 , xl2 , . . . , xlN−j−1 ] =∑
xij+1∈R(Xij+1 )
P [C = 0|x′i1 , x′i2 , . . . , x′ij+1 , xl1 , xl2 , . . . , xlN−j−1 , xij+1 ]·
P [Xij+1 = xij+1 |x′i1 , x′i2 , . . . , x′ij+1 , xl1 , xl2 , . . . , xlN−j−1 ] =∑
xij+1∈R(Xij+1 )
P [C = 0|x′i1 , x′i2 , . . . , x′ij , xij+1 , xl1 , xl2 , . . . , xlN−j−1 ]P [Xij+1 = xij+1 |x′ij+1 ] =
∑
xij+1∈R(Xij+1 )
e
β˜0+
N−j−1∑
n=1
βln (xln )+
j∑
m=1
β′im (x
′
im
)
eβij+1 (xij+1 )P [Xij+1 = xij+1 |x′ij+1 ] =
e
β˜0+
N−j−1∑
n=1
βln (xln )+
j∑
m=1
β′im (x
′
im
)
 ∑
xij+1∈R(Xij+1 )
eβij+1 (xij+1 )P [Xij+1 = xij+1 |x′ij+1 ]
 =
e
β˜0+
N−j−1∑
n=1
βln (xln )+
j∑
m=1
β′im (x
′
im
)+β′ij+1 (x
′
ij+1
)
.
Here, the third resultant is obtained using the fact that disease status is conditionally indepen-
dent of X ′ij+1 given Xij+1 and the fact that Xij+1 is conditionally independent of all other fac-
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tors given X ′ij+1 . The fourth resultant is obtained because, by assumption, the result holds for
the subsets Sj . Finally, in the final result, we have made the identification that β′ij+1(x′ij+1) =∑
xij+1∈R(Xij+1 )
eβij+1 (xij+1 )P [xij+1 |x′ij+1 ], i.e. a quantity that is a function only of x′ij+1 . Thus, the
posterior’s form is preserved for subsets of size j + 1.
Q.E.D.
Appendix F: Proof of AIM’s Consistency Under Disease Subtypes
Here we will only prove that AIM is a consistent model under the scenario of a heterogeneous
disease with multiple subtypes. While not shown here, the inconsistency of LR as a model for a
heterogeneous disease can be proven by counterexample, just as we have done for the missing and
surrogate factor confounding scenarios.
Suppose that there are K disease subtypes, each with a disease subtype status posterior of the
AIM form:
log(1− P (Dk = 1|x1, x2, . . . , xN )) = βk0 +
N∑
i=1
βkixi, k = 1, . . . ,K. (18)
Further, assume that these subtypes are conditionally independent given the observed factors
Xi, i = 1, . . . , N . Under these assumptions, we will prove that the heterogeneous disease status
C =
K⋃
k=1
Dk has a posterior that is also of the AIM form, i.e.
log(1− P (C = 1|x1, x2, . . . , xN )) = β0 +
N∑
i=1
βixi. (19)
Furthermore, βi =
K∑
k=1
βki, i = 1, . . . , N and β0 =
K∑
k=1
βk0. That is the strengths of each of the factors
for the heterogeneous disease is additive over the strengths for each of the subtypes. We note an
important implication of this result: to do inference on the heterogeneous disease using the AIM
model, one need not have any prior knowledge of how many (and whether in fact) multiple disease
subtypes exist for the given disease domain. On the other hand, since the LR form (if assumed to
be valid for the subtypes) is not preserved for the heterogeneous disease, such statement will not
hold for LR.
The proof of the theorem is as follows. We have (C = 0) ⇔
K⋂
k=1
(Dk = 0). Therefore, P (C =
0|x1, x2, . . . , xN ) = P (D1 = 0, D2 = 0, . . . , DK = 0|x1, x2, . . . , xN ). But since the disease subtypes
are conditionally independent given the factors, P (D1 = 0, D2 = 0, . . . , DK = 0|x1, x2, . . . , xN ) =
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K∏
k=1
P (Dk = 0|x1, . . . , xN ). Thus,
log(P (C = 0|x1, x2, . . . , xN ) =
K∑
k=1
log(P (Dk = 0|x1, . . . , xN ) (20)
=
K∑
k=1
(βk0 +
N∑
i=1
βkixi)
= (
K∑
k=1
βk0) +
N∑
i=1
xi(
K∑
k=1
βki)
= β0 +
N∑
i=1
xiβi,
where β0 =
K∑
k=1
βk0 and βi =
K∑
k=1
βki.
Q.E.D.
Appendix G: Proof of AIM and LR Detection Power Relationship for Synergistic
Interactions
Suppose there are N = 2 binary factors. Let plm ≡ P (C = 1|X1 = l,X2 = m), l ∈ {0, 1},m ∈ {0, 1}
be the true posterior probability of disease, for each of the four possible factor pair “genotypes”.
In this Appendix, we will prove that, if p10 ≥ p00 and p01 ≥ p00, then, for synergistic interactions
(defined by p11 ≥ p′11 as given in Theorem 4), AIM has a greater difference between its interaction
model and baseline model log-likelihoods than that for LR. Accordingly, since for both models the
log-likelihood difference (distributed as chi-squared with the same number of degrees of freedom) is
used to assess statistical significance of an interaction, the AIM model will produce strictly smaller
p-values than the LR model for synergistic interactions. The proof exploits the fact that there are
several ways one can determine the parameters of a logistic regression model. One way is of course
to estimate the model parameters to maximize the population data log-likelihood. However, an
alternative way to estimate LR parameter values is to determine them so as to be strictly consistent
with given posterior probabilities q00, q10, and q01. In particular, we note that, based on the LR
model form log(P (C = 1|X1, X2)/(1 − P (C = 1|X1, X2)) = β0 + β1X1 + β2X2. Thus, for the LR
model, strict consistency with q00, q10, and q01 means that:
q00
1−q00 = e
β0 , q101−q10 = e
β0+β1 , and q011−q01 =
eβ0+β2 . Thus, β0 = log(
q00
1−q00 ), β1 = log(
q10
1−q10 ) − log(
q00
1−q00 ), and β2 = log(
q01
1−q01 ) − log(
q00
1−q00 ).
Our proof of Theorem 4 is based on a consideration of three different LR models: i) the maximum
likelihood LR model; ii) the surrogate LR model with parameters determined by the true posteriors,
i.e. q00 = p00, q10 = p10, and q01 = p01; iii) the surrogate LR model with parameters determined
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by the maximum likelihood AIM model’s posteriors (denoted p
(A)
lm ), i.e. q00 = p
(A)
00 , q10 = p
(A)
10 ,
and q01 = p
(A)
01 . The proof structure is as follows. We first consider the surrogate LR model (LR’)
whose parameter values are determined by the (maximum likelihood) AIM model. Lemma 1 below
establishes some key results concerning this surrogate LR model and the maximum likelihood AIM
model. The next step is to establish a result (Lemma 2) that essentially says that a new model,
formed by mixing a given model’s probabilities with the true probabilities, necessarily has greater
data log-likelihood than the original, given model. Finally, we exploit these Lemmas, along with the
synergistic interaction assumption, to establish our (desired) detection power results. After stating
Lemma 1 and Lemma 2, we proceed with the proof of Theorem 4. Proofs for the two Lemmas are
given at the end of this Appendix.
Lemma 1: Let p
(A)
00 , p
(A)
01 , p
(A)
10 , p
(A)
11 denote the posterior disease probabilities, under the four factor
genotypes, for the baseline AIM model log(1 − P (C = 1|X)) = β′0 + β′1X1 + β′2X2, where the
parameter values β′0, β′1, β′2 maximize the model’s data log-likelihood on the given population. We
have the following results: 1) For the LR model (denoted LR’) whose parameters are determined
based on p
(A)
00 , p
(A)
01 , p
(A)
10 , we have p
(LR′)
00 = p
(A)
00 , p
(LR′)
01 = p
(A)
01 , p
(LR′)
10 = p
(A)
10 ; 2) Ordering Property:
Assuming p10 ≥ p00, p01 ≥ p00, p11 ≥ p10, and p11 ≥ p01, it follows that p(A)10 ≥ p(A)00 and p(A)01 ≥ p(A)00 ,
i.e. the MLE AIM model preserves the ordering of these posterior probabilities; 3) Under the same
assumptions as 2), p
(LR′)
11 ≥ p(A)11 with equality if and only if p(A)01 = p(A)00 or p(A)10 = p(A)00 .
Lemma 2: Consider an M -category phenotype (M ≥ 2), taking on values {ω1, . . . , ωM}, and a
population of individuals of size N =
M∑
m=1
Nm, Nm the number of individuals possessing phenotype
ωm. Let Q = {qm,m = 1, . . . ,M} be a probability mass function model for the phenotype,
and let P = {pm ≡ NmN ,m = 1, . . . ,M}, i.e. it is the empirical pmf. The data log-likelihood
for the population, under the model Q, is: L =
M∑
m=1
Nm log(qm) = N
M∑
m=1
pm log(qm). Consider
the new model Q′ = {λpm + (1 − λ)qm,m = 1, . . . ,M}, where 0 ≤ λ ≤ 1, with log-likelihood
L′ = N
M∑
m=1
pm log(q
′
m). Then, L
′ ≥ L with equality iff Q′ = Q.
We now prove Theorem 4, making use of Lemmas 1 and 2. We will only provide the proof
here for the synergistic interaction case, since the proof strategy is very similar for antagonis-
tic interactions. Let Nlm, l = 0, 1 m = 0, 1 denote the number of subjects in the population
with genotype (X1 = l,X2 = m). Then, the log-likelihood under the baseline AIM model
is: L(A) =
∑
l=0,1
∑
m=0,1
Nlm
(
plm log(p
(A)
lm ) + (1− plm) log(1− p(A)lm )
)
. Likewise, we have L(LR
′) =∑
l=0,1
∑
m=0,1
Nlm
(
plm log(p
(LR′)
lm ) + (1− plm) log(1− p(LR
′)
lm )
)
. Now, since, from Lemma 1, p
(LR′)
00 =
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p
(A)
00 , p
(LR′)
01 = p
(A)
01 , p
(LR′)
10 = p
(A)
10 , we have that
L(LR
′) − L(A) = (N11(p11 log(p(LR
′)
11 ) + (1− p11) log(1− p(LR
′)
11 ))− (21)
(N11(p11 log(p
(A)
11 ) + (1− p11) log(1− p(A)11 )),
a difference between two log-likelihoods, restricted to the subpopulation with (X1 = 1, X2 = 1).
We next consider the sign of the difference L(LR
′)−L(A) under the two possible cases: p11 ≥ p(LR
′)
11
and p11 < p
(LR′)
11 .
First, suppose p11 ≥ p(LR
′)
11 . Let λ = (p11 − p(LR
′)
11 )/(p11 − p(A)11 ). Note that λ ≥ 0 because
p11 ≥ p(LR
′)
11 and p11 ≥ p(A)11 . Also, λ < 1 because p(LR
′)
11 > p
(A)
11 and, thus, p11 − p(LR
′)
11 < p11 − p(A)11 .
Further, one can verify that (p
(LR′)
11 , 1− p(LR
′)
11 ) = λ(p
(A)
11 , 1− p(A)11 ) + (1− λ)(p11, 1− p11). Thus, by
Lemma 2, the log-likelihood (N11(p11 log(p
(LR′)
11 ) + (1− p11) log(1− p(LR
′)
11 )) is greater than the log-
likelihood (N11(p11 log(p
(A)
11 )+(1−p11) log(1−p(A)11 )) and, thus, L(LR
′) > L(A). Finally, the maximum
likelihood LR model has a log-likelihood L(LR) at least as large as L(LR
′), i.e. L(LR) ≥ L(LR′) > L(A).
Next, suppose p11 < p
(LR′)
11 . Let us construct the vector p(t) = (p00(t), p10(t), p01(t)), where
plm(t) = plm+ t(p
(A)
lm −plm). Note that p(0) = (p00, p10, p01) and p(1) = (p(A)00 , p(A)10 , p(A)01 ). As shown
in Lemma 1, the parameters of the LR model can be determined by these three probabilities and,
thus, by the triple p(t) (for any 0 ≤ t ≤ 1). Let us denote the resulting LR posterior probability,
given (X1 = 1, X2 = 1), by p
(LR′)
11 (t), a continuous function of t. Now, note that p
(LR′)
11 (1) = p
(LR′)
11 >
p11. Also, p
(LR′)
11 (0) = p
′
11 < p11, since this is just our definition of a synergistic interaction.
We thus have that p
(LR′)
11 (0) < p11 < p
(LR′)
11 (1). Since p
(LR′)
11 (t) is a continuous function, by the
intermediate value theorem, there must be some value tc, 0 < tc < 1, such that p
(LR′)
11 (tc) = p11.
Let us consider the log-likelihood for this model, L(LR
′)(tc), which can be written as L
(LR′)(tc) =∑
l=0,1
∑
m=0,1
L
(LR′)
lm (tc), where L
(LR′)
lm (tc) = Nlm(plm log(p
(LR′)
lm (tc))+(1−plm) log(1−p(LR
′)
lm (tc))). Now,
for (l,m) = (0, 0), (0, 1), and(1, 0), we have that (p
(LR′)
lm (tc), 1−p(LR
′)
lm (tc)) = tc(p
(A)
lm , 1−p(A)lm )+(1−
tc)(plm, 1− plm). Recalling that 0 < tc < 1 and applying Lemma 2, we have that L(LR
′)
lm (tc) > L
(A)
lm ,
(l,m) = (0, 0), (1, 0), (0, 1), where L
(A)
lm is the log-likelihood for the (X1 = l,X2 = m) subpopulation
under the AIM posterior model. Finally, since p
(LR′)
11 (tc) = p11, we have (p
(LR′)
11 (tc), 1−p(LR
′)
11 (tc)) =
λ(p11, 1 − p11) + (1 − λ)(p(A)11 , 1 − p(A)11 ), where λ = 1. Thus, again applying Lemma 2, we have:
L
(LR′)
11 (tc) > L
(A)
11 .
Since all four genotype-conditioned log-likelihoods for the LR model determined based on p(tc)
are greater than their counterpart log-likelihoods for the maximum likelihood AIM model, we have,
for the composite log-likelihoods, that L(LR
′)(tc) > L
(A). Moreover, the maximum likelihood LR
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model has log-likelihood L(LR) ≥ L(LR′)(tc). Thus, we again obtain L(LR) > L(A).
In summary, under both possible scenarios (p11 ≥ p(LR
′)
11 and p11 < p
(LR′)
11 ), L
(LR) > L(A).
Finally, for hypothesis testing, we look at the difference between the log-likelihood under the
alternative hypothesis (where an interaction term β3X1X2 is included in the model), LAlt, and
the baseline model log-likelihood. Now, under the alternative hypothesis, for both AIM and LR,
the models are saturated, i.e. there are four genotype values and four free parameters. Thus, the
AIM and LR alternative hypothesis maximum likelihood models have the same log-likelihood value
Lalt (Hosmer(2013)), which must be at least as large as the baseline model log-likelihoods. Thus,
Lalt ≥ L(LR), and since L(LR) > L(A), we have Lalt − L(LR) < Lalt − L(A), i.e. AIM gives a greater
log-likelihood difference.
Q.E.D.
Proof of Lemma 1:
First Result: Under the AIM model, p
(A)
00 = 1 − eβ
′
0 , p
(A)
10 = 1 − eβ
′
0+β
′
1 , and p
(A)
01 = 1 − eβ
′
0+β
′
2 .
Now, consider the LR model whose parameters are determined based on the AIM model’s posterior
probabilities p
(A)
00 , p
(A)
10 , p
(A)
01 , rather than based on the true disease posteriors p00, p10, p01. Accord-
ingly, we let β0 = log(
p
(A)
00
1−p(A)00
), β1 = log(
p
(A)
10
1−p(A)10
) − log( p
(A)
00
1−p(A)00
), and β2 = log(
p
(A)
01
1−p(A)01
) − log( p
(A)
00
1−p(A)00
).
Based on these parameter value assignments, the LR posterior probabilities are:
p
(LR′)
00 = e
β0/(1 + eβ0)|
β0=log(
p
(A)
00
1−p(A)
00
)
= p
(A)
00 (22)
p
(LR′)
10 = e
β0+β1/(1 + eβ0+β1)|
β0=log(
p
(A)
00
1−p(A)
00
),β1=log(
p
(A)
10
1−p(A)
10
)−log( p
(A)
00
1−p(A)
00
)
= p
(A)
10 .
Likewise, it is also found that p
(LR′)
01 = p
(A)
01 .
Second Result:
The log-likelihood under an AIM model is:
L =
∑
l=0,1
∑
m=0,1
plm log(p
(A)
lm ), (23)
where p
(A)
00 = 1−eβ0 , p(A)10 = 1−eβ0+β1 , p(A)01 = 1−eβ0+β2 , and p(A)11 = 1−eβ0+β1+β2 . The maximum
likelihood AIM model satisfies the necessary optimality conditions: ∂L/∂βi = 0, i = 0, 1, 2. Taking
derivatives, we find that these conditions are:
∂L
∂β0
=
∑
l=0,1
∑
m=0,1
Nlm
(
p
(A)
lm − plm
p
(A)
lm
)
= 0 (24)
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∂L
∂β1
= N10
(
p
(A)
10 − p10
p
(A)
10
)
+N11
(
p
(A)
11 − p11
p
(A)
11
)
= 0
∂L
∂β2
= N01
(
p
(A)
01 − p01
p
(A)
01
)
+N11
(
p
(A)
11 − p11
p
(A)
11
)
= 0.
Now, note that the term N11
(
p
(A)
11 −p11
p
(A)
11
)
is common to the β1 and β2 derivative conditions. Thus,
we have that N10
(
p
(A)
10 −p10
p
(A)
10
)
= N01
(
p
(A)
01 −p01
p
(A)
01
)
= −N11
(
p
(A)
11 −p11
p
(A)
11
)
. Further, since Nlm > 0 and
p
(A)
lm > 0∀l,m, this equality implies two possible cases: 1) p(A)10 ≥ p10, p(A)01 ≥ p01, and p(A)11 ≤ p11; 2)
p
(A)
10 ≤ p10, p(A)01 ≤ p01, and p(A)11 ≥ p11.
Assuming the first case, we then haveB ≡ N10
(
p
(A)
10 −p10
p
(A)
10
)
= N01
(
p
(A)
01 −p01
p
(A)
01
)
= −N11
(
p
(A)
11 −p11
p
(A)
11
)
≥
0. Thus, for this case, the derivative condition for β0 can be re-expressed as:
∂L
∂β0
=
(
p
(A)
00 −p00
p
(A)
00
)
+
B+B−B = 0, B ≥ 0. Equality can only be satisfied if the first term is non-positive, which requires
p
(A)
00 ≤ p00. However, since p10 ≥ p00 and p01 ≥ p00, this implies p(A)10 ≥ p(A)00 and p(A)01 ≥ p(A)00 .
Next, consider the second case. Suppose that p
(A)
10 < p
(A)
00 . This implies that β1 > 0, which
implies that p
(A)
11 < p
(A)
10 . Moreover, p
(A)
10 ≤ p10. Thus, p(A)11 < p(A)10 ≤ p10 ≤ p11. However, under this
case we also have that p
(A)
11 ≥ p11. Thus, the assumption that p(A)10 < p(A)00 leads to a contradiction.
Applying the same logic, one can show, for this case, that p
(A)
01 < p
(A)
00 also leads to contradiction.
Thus, for this case, we must have p
(A)
10 ≥ p(A)00 and p(A)01 ≥ p(A)00 .
Under both possible cases (and thus, in general), we have: p
(A)
10 ≥ p(A)00 and p(A)01 ≥ p(A)00 . Q.E.D.
Third Result:
p
(LR′)
11
1− p(LR′)11
= eβ0+β1+β2 =
eβ0+β1eβ0+β2
eβ0
(25)
=
(p
(LR′)
10 /(1− p(LR
′)
10 ))(p
(LR′)
01 /(1− p(LR
′)
01 ))
(p
(LR′)
00 /(1− p(LR
′)
00 ))
.
With simple algebra, we obtain:
1− p(LR′)11 =
(1− p(LR′)01 )(1− p(LR
′)
10 )p
(LR′)
00
p
(LR′)
01 p
(LR′)
10 (1− p(LR
′)
00 )
p
(LR′)
11 (26)
=
(1− p(A)01 )(1− p(A)10 )p(A)00
p
(A)
01 p
(A)
10 (1− p(A)00 )
p
(LR′)
11 .
Solving for p
(LR′)
11 , we then obtain:
p
(LR′)
11 =
p
(A)
01 p
(A)
10 (1− p(A)00 )
p
(A)
00 − p(A)01 p(A)00 − p(A)10 p(A)00 + p(A)01 p(A)10
. (27)
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Correspondingly, for the maximum likelihood model of AIM form log(1 − P (C = 1|X1, X2))) =
β′0 + β′1X1 + β′2X2, we have β′0 = log(1− p(A)00 ), β′1 = log(1−p
(A)
10
1−p(A)00
), and β′2 = log(
1−p(A)01
1−p(A)00
). Thus,
1− p(A)11 = eβ
′
0+β
′
1+β
′
2 =
(1− p(A)10 )(1− p(A)01 )
(1− p(A)00 )
and (28)
p
(A)
11 = 1−
(1− p(A)10 )(1− p(A)01 )
(1− p(A)00 )
.
Now, let us check the sign of p
(LR′)
11 − p(A)11 . We can write:
p
(LR′)
11 − p(A)11 = (1− p(LR
′)
11 )
(
(1− p(A)11 )
(1− p(LR′)11 )
− 1
)
(29)
= (1− p(LR′)11 )
(
p
(A)
01 p
(A)
10
p
(A)
00 p
(LR′)
11
− 1
)
,
where the latter expression is obtained using (26) and (28).
We now compare
p
(A)
01 p
(A)
10
p
(A)
00 p
(LR′)
11
to 1. First, using (27), we have:
p
(A)
01 p
(A)
10
p
(A)
00 p
(LR′)
11
=
p
(A)
00 − p(A)00 p(A)01 − p(A)00 p(A)10 + p(A)01 p(A)10
p
(A)
00 (1− p(A)00 )
(30)
=
p
(A)
01 (p
(A)
10 − p(A)00 ) + p(A)00 − p(A)00 p(A)10
p
(A)
00 (1− p(A)00 )
=
(p
(A)
01 − p(A)00 )(p(A)10 − p(A)00 ) + p(A)00 (p(A)10 − p(A)00 ) + p(A)00 − p(A)00 p(A)10
p
(A)
00 (1− p(A)00 )
=
(p
(A)
01 − p(A)00 )(p(A)10 − p(A)00 ) + p(A)00 (1− p(A)00 )
p
(A)
00 (1− p(A)00 )
.
Now, since (p
(A)
01 − p(A)00 ) ≥ 0 and (p(A)10 − p(A)00 ) ≥ 0, the final expression must also be greater than
or equal to 1. Thus, we have
p
(A)
01 p
(A)
10
p
(A)
00 p
(LR′)
11
≥ 1. Now, examining (29) and noting that 1 − p(LR′)11 > 0,
we have finally proved that p
(LR′)
11 ≥ p(A)11 . Furthermore, examining (p(A)01 − p(A)00 )(p(A)10 − p(A)00 ) in the
final expression in (30), it is seen that this expression equals 1, and, thus, p
(LR′)
11 = p
(A)
11 , if and only
if p
(A)
01 = p
(A)
00 or p
(A)
10 = p
(A)
00 .
Q.E.D.
Proof of Lemma 2:
L′ − L = N
M∑
m=1
pm log(q
′
m)−N
M∑
m=1
pm log(qm) (31)
55
= N
M∑
m=1
pm log(λpm + (1− λ)qm)−N
M∑
m=1
pm log(qm)
≥
M∑
m=1
(λpm log(pm) + (1− λ)pm log(qm)−
M∑
m=1
pm log(qm)
= λ
M∑
m=1
pm log(
pm
qm
) = λDKL(P||Q) ≥ 0.
Here, the first inequality is obtained from Jensen’s inequality applied to the logarithm function, and
DKL(P||Q) is the Kullback-Leibler distance between pmfs (which is non-negative). Thus, L′ ≥ L.
Note that equality is achieved if λ = 0, in which case q′m = qm∀m. Moreover, since the log() is
strictly concave, again by Jensen’s inequality, equality is only possible for λ = 0 or 1; in this case,
only if q′m = qm∀m.
Q.E.D.
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